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Abstract
The folate metabolic pathway is important in several biological processes, including purine and pyrimidine
synthesis and the methylation of DNA and proteins. There are several pathologies that are associated with
dysregulation of the folate/homocysteine (Hcy) metabolic pathway, including rheumatoid arthritis (RA),
cardiovascular disease (CVD), and several cancers. Many of the pathologies associated with altered folate/
Hcy metabolism have underlying inflammatory etiology. The distribution of folate derivatives can be
influenced by nutrient deficiency or insufficiency and by genetic polymorphisms in important enzymes in the
pathway. Additionally, antifolate drugs, such as methotrexate (MTX) and pemetrexed (PMX), modify folate/
Hcy metabolism.
The relationships between folate phenotype, genetic polymorphisms of folate pathway enzymes, and
inflammatory proteins were examined in both population-based and cell culture studies. A study set of young
adults was used to study these relationships in a healthy population. In females, MCP-1 concentrations were
positively correlated with Hcy and negatively correlated with both serum and red blood cell folate; female
MTHFR 677T carriers had particularly elevated MCP-1 concentrations. In an observational follow-up study
of patients prescribed MTX, total folate concentration decreased and MCP-1 concentration increased
between their initial (i.e. before starting MTX) and on-drug treatment visits. MTHFR 677C>T genotype was
associated with changes in several of the clinical and biochemical variables examined. Additionally, changes in
MCP-1 and IL-8 concentrations were positively correlated with one another.
Treatment of EA.hy 926 endothelial cells with PMX caused a decrease in individual folate analytes in both
cells adapted to growth in low folate conditions and folate-replete cells. Several genes were significantly up or
down-regulated in PMX-treated Lo cells. Additionally, IL-8 and C3 protein concentrations were increased
following PMX treatment in cells grown under low folate conditions. PMX drug treatment was shown in this
study to have effects that lead to an increase in pro-inflammatory mediators in these folate-deplete cells.
In a study of lung cancer patients and matched controls, the lung cancer cases had higher total red blood cell
(RBC) folate and RBC 5-MTHF concentrations. Additionally, there were 38 MTHFR 677TT homozygotes in
the cases, but only 24 controls had this genotype.
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ABSTRACT 
 
Genetic Polymorphisms and Antifolate Drug Treatment Can Alter Folate/Homocysteine 
Metabolism and Inflammatory Protein Profile 
 
Andrea L. Hammons 
 
Supervisor: Alexander S. Whitehead, D. Phil. 
 
The folate metabolic pathway is important in several biological processes, including 
purine and pyrimidine synthesis and the methylation of DNA and proteins. There are 
several pathologies that are associated with dysregulation of the folate/homocysteine 
(Hcy) metabolic pathway, including rheumatoid arthritis (RA), cardiovascular disease 
(CVD), and several cancers. Many of the pathologies associated with altered folate/Hcy 
metabolism have underlying inflammatory etiology. The distribution of folate derivatives 
can be influenced by nutrient deficiency or insufficiency and by genetic polymorphisms 
in important enzymes in the pathway. Additionally, antifolate drugs, such as methotrexate 
(MTX) and pemetrexed (PMX), modify folate/Hcy metabolism. 
The relationships between folate phenotype, genetic polymorphisms of folate pathway 
enzymes, and inflammatory proteins were examined in both population-based and cell 
culture studies. A study set of young adults was used to study these relationships in a 
healthy population. In females, MCP-1 concentrations were positively correlated with 
Hcy and negatively correlated with both serum and red blood cell folate; female MTHFR 
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677T carriers had particularly elevated MCP-1 concentrations. In an observational 
follow-up study of patients prescribed MTX, total folate concentration decreased and 
MCP-1 concentration increased between their initial (i.e. before starting MTX) and on-
drug treatment visits. MTHFR 677C>T genotype was associated with changes in several 
of the clinical and biochemical variables examined. Additionally, changes in MCP-1 and 
IL-8 concentrations were positively correlated with one another.  
Treatment of EA.hy 926 endothelial cells with PMX caused a decrease in individual 
folate analytes in both cells adapted to growth in low folate conditions and folate-replete 
cells. Several genes were significantly up or down-regulated in PMX-treated Lo cells. 
Additionally, IL-8 and C3 protein concentrations were increased following PMX 
treatment in cells grown under low folate conditions. PMX drug treatment was shown in 
this study to have effects that lead to an increase in pro-inflammatory mediators in these 
folate-deplete cells. 
In a study of lung cancer patients and matched controls, the lung cancer cases had higher 
total red blood cell (RBC) folate and RBC 5-MTHF concentrations. Additionally, there 
were 38 MTHFR 677TT homozygotes in the cases, but only 24 controls had this 
genotype. 
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Chapter 1 
General Introduction 
 
1.1 Folate Metabolism 
Folate (vitamin B9) is a B vitamin involved in one-carbon metabolism that is critically 
important for optimal cell function, as it is involved in purine and pyrimidine synthesis, 
methylation of DNA and proteins, and glutathione production. Hyperhomocysteinemia 
(HHcy) a condition defined by elevated total Hcy (tHcy – the sum of circulating Hcy 
species) levels, has been associated with several pathologies, including cardiovascular 
disease and stroke (Refsum et al. 1998), RA (Wallberg-Jonsson et al. 2002, Chiang et al. 
2003), neural tube defects (NTDs) in offspring (van der Put et al. 2001), Alzheimer’s 
disease (Clarke et al. 1998), systemic lupus erythematosus (SLE) (Von Feldt et al. 2006),  
and several cancers (Ueland et al. 2001). Hcy, an intermediate in the folate metabolic 
pathway, is usually high when folate levels are low. 
 
In addition to being associated with low folate levels, risk factors for elevated tHcy 
include coffee and alcohol consumption, smoking, and lack of exercise (Schneede, 
Refsum & Ueland 2000). Being male is also associated with elevated tHcy levels 
(Schneede, Refsum & Ueland 2000), though tHcy levels increase with age in both sexes 
(Refsum et al. 1998). For healthy adults, 400 μg of folate per day is recommended. From 
1998, by FDA mandate, flour and other grain products have been fortified with FA in the 
United States to reduce the incidence of NTDs in newborns. 
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1.1.1 Folate Transport 
Humans cannot synthesize folate, and must obtain this vitamin from food sources, such 
as leafy green vegetables. 5-methyltetrahydrofolate (5-MTHF) and 
formyltetrahydrofolate are the main naturally occurring forms of folate in food. FA is a 
synthetic analog of folate; it is the fully oxidized form of folate, which is used for 
fortification of food and in vitamin supplements.  
 
Naturally occurring folates are polyglutamated, and must be reduced to the 
monoglutamate form by the enzyme γ-glutamyl hydrolyase in the intestine before they 
can be absorbed into the bloodstream (Stover 2004); the main circulating form of folate is 
5-MTHF. Folate can be transported into cells via membrane-bound carriers or a specific 
folate binding protein, the reduced folate carrier (RFC1). The latter is a very important 
carrier involved in folate transport. Folate is polyglutamated by folylpolyglutamate 
synthase (FPGS) (Stover 2004) and is then unable to leave the cell allowing it to 
accumulate. Measurement of folate in RBCs is representative of long-term folate status 
because RBCs circulate for about 120 days in the body before their components are 
recycled, whereas measurement of folate in the plasma is subject to day to day dietary 
fluctuation. 
 
1.1.2 The Folate/Homocysteine Metabolic Pathway 
The folate metabolic pathway is made up of two sub-pathways (Figure 1): one facilitates 
the methylation of substrates such as DNA and proteins and the other supports the 
generation of thymidylate and purines.  
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Folate enters the cell as 5-MTHF, which provides the methyl group for methionine 
synthase (MTR) to remethylate Hcy to methionine in a reaction that also generates 
tetrahydrofolate (THF). MTR requires cobalamin (vitamin B12) as a cofactor, which is 
kept in its active form by methionine synthase reductase (MTRR). Methionine 
adenosyltransferase in turn converts methionine to S-adenosylmethionine (SAM), the 
methyl donor for a multitude of methylation reactions in which SAM is converted into S-
adenosylhomocysteine (SAH).  SAH hydrolase then converts SAH to Hcy, completing 
the cycle. If this subpathway is insufficient to remethylate Hcy to methionine, the former 
accumulates and triggers the transsulfuration pathway in the liver and kidney, where the 
B6-dependent enzyme cystathionine-β-synthase (CBS) is expressed (Durand et al. 2001). 
In this pathway, converts Hcy to cystathionine which is then converted to cysteine, which 
can ultimately lead to glutathione production. In the liver, excess Hcy can be 
remethylated to methionine by betaine-homocysteine S-methyltransferase (BHMT) using 
betaine as the methyl donor. As the liver processes up to approximately half of the 
methionine ingested by humans (Mato et al. 1997), this pathway could be an important 
regulator of tHcy. 
 
THF is back-converted to 5,10-methylenetetrahydrofolate (5,10-MeTHF) by serine 
hydroxymethlytransferase (SHMT). 5-MTHF is produced intracellularly via the 
conversion of 5,10-MeTHF by methylenetetrahydrofolate reductase (MTHFR). 5,10-
MeTHF acts as a methyl donor for thymidylate synthase (TYMS), which converts 2’-
deoxyuridine monophosphate (dUMP) to 2’-deoxythymidine 5’-monophosphate (dTMP). 
Purine synthesis occurs with the conversion of 10-formyltetrahydrofolate (10-FTHF) to 
THF. Another key enzyme in this pathway is dihydrofolate reductase (DHFR), which 
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reduces dihydrofolate (DHF) to THF. DHFR also converts FA to DHF and then to THF 
to permit the synthetic form acquired from supplements and fortified foods to join the 
pool of natural folates. 
 
 
Figure 1-1  Folate/homocysteine metabolic pathway. 5-MTHF: 5-
methyltetrahydrofolate; THF: tetrahydrofolate; 5,10-MTHF: 5,10-
methenyltetrahydrofolate; 5,10-MeTHF: 5,10-methylenetetrahydrofolate; DHF: 
dihydrofolate; Hcy:, homocysteine; dUMP: deoxyuridine monophosphate; dTMP: 
deoxythymidine monophosphate; SAH: S-adenosylhomocysteine; SAM: S-
adenosylmethionine; RFC1: reduced folate carrier; MTHFR: methylenetetrahydrofolate 
reductase; DHFR: dihydrofolate reductase; TYMS: thymidylate synthase; CBS: 
cystathionine-β-synthase; MTR: methionine synthase; MTRR: methionine synthase 
reductase; SHMT: serine hydroxymethyltransferase; MTX: methotrexate; PMX: 
pemetrexed. 
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1.2 Pathologies Associated with Perturbations in Folate Metabolism 
Although a low folate/high Hcy phenotype has been associated with a number of human 
pathologies, a causal relationship has only been established for NTDs. The following 
sections detail the ways in which perturbations in folate/Hcy metabolism could contribute 
to pathologies related to the current study. 
 
1.2.1 Cardiovascular Disease 
Arteriosclerosis refers to a group of diseases characterized by thickening and hardening 
of the arterial walls. Atherosclerosis, a form of arteriosclerosis, is a disease of chronic 
inflammation associated with the buildup of lipids in the arterial walls. Chemokines 
promote directed migration of inflammatory cells, and some are involved in the 
pathogenesis of atherosclerosis. In the development of an atherosclerotic plaque, low-
density lipoprotein (LDL) moves into the subendothelium and is oxidixed by free radicals 
that have been generated by macrophages. Macrophages then engulf oxidized LDL, 
forming foam cells. Additional monocytes are attracted by the release of growth factors 
and cytokines. Deposition of lipids within these cells leads to the formation and 
enlargement of atherosclerotic lesions (Faxon et al. 2004). Monocyte chemoattractant 
protein-1 (MCP-1), which is encoded by the CCL2 gene (Graves, Jiang 1995), is a 
chemokine that recruits monocytes into the subendothelial cell layer.  
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Figure 1-2  Formation of an atherosclerotic lesion (Faxon et al. 2004). 
 
In cell culture studies, expression and secretion of MCP-1 and IL-8 are upregulated in 
human aortic endothelial cells in the presence of concentrations of Hcy comparable to 
pathophysiological levels observed in homocystinuric subjects (Poddar et al. 2001). This 
suggests that Hcy may contribute directly to the initiation and progression of vascular 
disease by promoting leukocyte recruitment mediated by MCP-1 and/or IL-8. Carotid 
arteries in HHcy mice that had normal folate status had increased permeability and 
stiffness, both of which are features of CVD (Mullick et al. 2006).  FA inhibited the 
progression of atherosclerosis in apoE-deficient mice by reducing the atherosclerotic 
lesion area, acting independently of Hcy lowering (Carnicer et al. 2007). In healthy 
human adults, it has been shown that elevated Hcy after a methionine load impairs flow-
mediated endothelium-dependent vasodilation and induces endothelial dysfunction, 
which is an early event in atherogenesis (Bellamy et al. 1998, Hanratty et al. 2001). In 
humans, FA lowers Hcy levels (Ward et al. 1997), but has also been shown to improve 
endothelial dysfunction independent of Hcy lowering (Verhaar et al. 1998, Doshi et al. 
2002). HHcy induces atherosclerosis and increases chemokine secretion in patients, 
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which is reversed by low-dose FA treatment, perhaps due to lowering of Hcy (Wang et 
al. 2005). These data demonstrate that it is unclear whether arterial function is affected 
indirectly through mild HHcy or by folate levels in a Hcy-independent manner. 
 
1.2.2 Cancer 
There are two proposed mechanisms by which folate deficiency may increase cancer risk. 
The first is that impaired synthesis of dTMP resulting from folate deficiency increases 
rates of uracil misincorporation into DNA; the second is that depressed SAM synthesis 
leads to decreased methylation, which is a nearly universal finding in tumorigenesis 
(Choi, Mason 2000).  A number of cancers have been linked to folate deficiency, 
including colon, cervical, and head and neck cancers (Choi, Mason 2000, Ma et al. 1997). 
Several studies suggest that there is a relationship between dietary folate intake and lung 
cancer. A reciprocal relationship between folate and lung cancer risk has been shown in 
both a case-control study of a racially heterogeneous Texas population of former smokers 
(Shen et al. 2003), and a prospective cohort study of Dutch males (Voorrips et al. 2000). 
In contrast, a more recent study using data from two trials with long-term follow-up 
showed an increase in lung cancer incidence with FA supplementation (Ebbing et al. 
2009). Taken together, these results present an unclear picture of the relationship between 
folate and the etiology of lung cancer, and as such this is a topic of interest that needs to 
be further studied and elucidated. 
 
Several groups have also reported that functional polymorphisms of genes associated 
with folate metabolism may confer an increased risk of lung cancer, including MTHFR 
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(Jeng et al. 2003, Shi et al. 2005b, Boccia et al. 2010), MTR and MTRR (Shi et al. 2005a) 
and TYMS (Shi et al. 2005c).  
 
1.3 Causes of Perturbations in Folate Metabolism 
1.3.1 Influence of Vitamins on Folate Metabolism 
In addition to folate, several other B vitamins are necessary for the proper function of the 
folate metabolic pathway. MTHFR requires riboflavin (vitamin B2) as a coenzyme in the 
form of flavin adenine dinucleotide (FAD). Riboflavin plays an important role in the 
folate pathway and has been shown to lower tHcy in individuals homozygous for the 
MTHFR 677C>T polymorphism (Hustad et al. 2000, Jacques et al. 2002).  
 
The enzyme methionine synthase requires vitamin B12 as a cofactor for the remethylation 
of Hcy to methionine. Increased levels of vitamin B12 have been associated with 
decreased plasma Hcy in individuals who were heterozygous for both the MTHFR 
677C>T and 1298A>C variants, with nonsignificant trends in individuals homozygous 
for either the 677C>T or 1298A>C variants. In the same study, there was no decrease in 
Hcy in individuals with the wild-type genotype for both of the variants; these data 
suggest that enhancing vitamin B12 status may significantly decrease tHcy in individuals 
with 677C>T and/or 1298A>C MTHFR polymorphisms (Bailey et al. 2002). Vitamin B12 
concentration is generally considered to be less predictive of tHcy levels than folate 
concentration. However, evidence suggests that vitamin B12 becomes an important 
nutritional determinant of tHcy in individuals who have adequate folate. Under 
conditions of low folate status, the effect of folate predominates (McNulty et al. 2008). 
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Intake of vitamin B6, a cofactor for CBS, has also been inversely associated with tHcy 
(Selhub et al. 1993). While fasting tHcy level is usually normal in subjects with vitamin 
B6 deficiency or mild defects in CBS, but the postmethionine load level is increased 
(Refsum et al. 1998). 
 
1.3.2 Influence of Common Functional Polymorphisms on Folate Metabolism 
Functional polymorphisms in several of the enzymes can affect the distribution of folate 
intermediates in the pathway and lead to increased levels of tHcy.  
 
The most important, and consequently most widely studied, single nucleotide 
polymorphism (SNP) in the pathway is the MTHFR 677C>T polymorphism. This 
transition causes an alanine to valine substitution at residue 222 in the catalytic domain of 
the enzyme, forming a thermolabile variant of the enzyme that is less efficient at 
converting 5,10-MeTHF to 5-MTHF. The MTHFR 677TT genotype has been associated 
with higher levels of tHcy when folate levels are low (Kluijtmans et al. 2003, Jacques et 
al. 1996, Harmon et al. 1996). Consensus in the literature suggests that TT homozygotes 
who are folate-replete have similar tHcy levels to their CC and CT peers. Thus, in a 
population with adequate folate intake, either via a folate rich diet, fortified food, or 
supplement use, MTHFR genotype has little effect. 
 
There are several other functional polymorphisms in enzymes in the folate metabolic 
pathway that alter Hcy levels, including MTHFR 1298A>C, MTR 2756A>G (Harmon et 
al. 1999, Tsai et al. 2000), MTRR 66A>G (Gaughan et al. 2001), and TYMS 3’UTR 
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ins/del (Kealey et al. 2005). Homozygotes for the CBS 844ins68 insertion are relatively 
rare, but heterozygotes for this variant have decreased THcy (Tsai et al. 2000) and 
coronary artery disease (Janosikova et al. 2003). The TYMS 5’UTR contains a tandem 
repeat element that is polymorphic with respect to copy number (i.e. usually two or three 
copies) (Horie et al. 1995). The 3R allele confers higher translational efficiency (Horie et 
al. 1995) and has been associated with increased TYMS protein levels and higher enzyme 
activity (Kawakami et al. 1999), although there is not a significant effect on tHcy 
concentrations.  
 
As with the MTHFR 677C>T polymorphism, the other polymorphisms cause 
predispositions to higher or lower tHcy levels. Often, the Hcy-raising effect of the 
MTHFR 677C>T polymorphism is greater when in combination with other Hcy-raising 
enzyme polymorphisms in the pathway. In other cases, there may be a ‘normalization’ of 
tHcy levels when the other polymorphism lowers tHcy. For example, the CBS 844ins68 
allele appears to ‘counterbalance’ the Hcy-raising and folate-lowering effect of the 
MTHFR 677TT genotype. In this case, MTHFR 677TT/CBS 844ins68 carriers have tHcy 
and folate concentrations that are similar to those of MTHFR 677CT heterozygotes or CC 
homozygotes (Summers et al. 2008). 
 
1.3.3 Antifolate Drugs 
Antifolate drugs are analogs of FA which have a greater affinity for their target 
enzyme(s) than the enzyme substrates and therefore are considered anti-metabolites. 
When antifolate drugs enter cells they are polyglutamated via the same mechanism as 
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naturally occurring folates. This prevents the drugs from leaving the cell and increases 
their affinity for their target. Antifolate drugs are important in cancer chemotherapy 
because they inhibit enzymes involved in purine and pyrimidine synthesis, whereby they 
are able to interfere with tumor growth and division. As such, they have been used for the 
treatment of cancer for several decades. Classical antifolate drugs, such as methotrexate 
(MTX), act by primarily inhibiting one enzyme in the folate metabolic pathway (in this 
case, DHFR). Research for the development of new antifolate drugs is ongoing, including 
a new generation of multi-targeted antifolates; the exemplar for this new generation is 
pemetrexed (PMX), which has been approved for the treatment of pleural mesothelioma 
and non-small cell lung carcinoma. PMX acts by inhibiting TYMS, DHFR, and 
glycinamide ribonucleotide formyltransferase (GARFT), an enzyme that transfers a 
formyl group of 10-FTHF in the formation of THF. 
 
In addition to being used in the treatment of certain cancers, MTX is used as a disease-
modifying antirheumatic drug (DMARD) at low doses for the treatment of several 
inflammatory diseases in addition to RA (Weinblatt et al. 1985, Kremer, Lee 1986). 
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1.4 Summary and Specific Aims 
The folate metabolic pathway is important in several biological processes, including 
purine and pyrimidine synthesis and the methylation of DNA and proteins. There are 
several pathologies that are associated with dysregulation of the folate/Hcy metabolic 
pathway, including RA, SLE, cardiovascular disease, and several cancers. Nutrient 
deprivation and genetic polymorphisms in important enzymes in the pathway can affect 
the distribution of folate derivatives. Additionally, antifolate drugs, such as MTX and 
PMX, modify folate/Hcy metabolism. 
 
The specific aims of the research reported here include: 
 
1)  To examine the relationship between folate/Hcy phenotypes and MTHFR 
677C>T genotype on serum levels of MCP-1 in healthy individuals, 
2)  To examine the relationship between folate/Hcy phenotype and several folate 
pathway polymorphisms in lung cancer cases and matched controls, 
3) To examine the effects of PMX drug treatment on inflammatory gene expression 
in an established Ea.hy 926 endothelial cell line, and  
4)  To examine the effects of MTX drug treatment on patients with rheumatoid 
arthritis. 
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Chapter 2 
Folate/Homocysteine Phenotypes and MTHFR 677C>T Genotypes are 
Associated with Serum Levels of Monocyte Chemoattractant Protein-1 
 
2.1 Abstract 
MCP-1 is a chemokine that recruits monocytes into the subendothelial cell layer in 
atherosclerotic lesions. Elevated Hcy (hyperhomocysteinemia), which is usually 
associated with low folate status, is a known risk factor for many pathologies with 
inflammatory etiologies. The present study was undertaken to examine whether there are 
associations between MCP-1 concentrations and folate/Hcy phenotype or MTHFR 
677C>T genotype in healthy young adults. In females, MCP-1 concentrations were 
positively correlated with Hcy and negatively correlated with both serum and red blood 
cell folate; female smokers and MTHFR 677T carriers had particularly elevated MCP-1 
concentrations. Similar relationships were not seen in males. These findings may have 
implications for understanding the female predominance observed for a range of 
autoimmune diseases, such as SLE and RA. 
 
2.2 Introduction 
HHcy, defined by circulating blood levels of tHcy ≥13 μmol/L, is associated with several 
pathologies including CVD, stroke (Refsum et al. 1998), NTDs in offspring (van der Put 
et al. 2001), certain cancers (Ueland et al. 2001), and RA (Wallberg-Jonsson et al. 2002, 
Chiang et al. 2003). tHcy is also elevated in patients with SLE (Von Feldt et al. 2006), an 
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inflammatory disease that mainly affects young women and is associated with high 
cardiovascular comorbidity. 
 
Hcy concentrations are affected by the availability of B vitamins, especially folate. They 
are also influenced by functional polymorphisms in key enzymes in the folate/Hcy 
metabolic pathway that can affect the distribution of the intermediates in the pathway and 
lead to elevated Hcy. Of these polymorphisms, the MTHFR 677C>T polymorphism has 
the greatest quantitative effect, with the 677TT genotype being associated with relatively 
high Hcy concentrations, particularly when folate status is low (Jacques et al. 1996, 
Harmon et al. 1996).  
 
Elevated Hcy may be indicative of an underlying dysregulation of folate/Hcy 
metabolism. Several of the pathologies that are associated with folate/Hcy dysregulation 
have inflammatory components.  However, the relationship between folate/Hcy 
phenotypes and inflammatory mediators has not been fully elucidated. Chemokines, 
which promote directed migration of inflammatory cells, are important components of the 
pathogenesis of atherosclerosis. MCP-1 is a chemokine, encoded by the CCL2 gene 
(Graves, Jiang 1995), that recruits monocytes into the subendothelial cell layer in 
atherosclerotic lesions. MCP-1 is also important in the recruitment of macrophages and 
leukocytes into the glomeruli and interstitial spaces of the kidney, and is consequently a 
significant contributor to nephritis, a major cause of morbidity and mortality in SLE 
(Noris et al. 1995). Additionally, this chemokine is highly expressed in serum, synovial 
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tissue and synovial fluid in patients with RA, another inflammatory disease (Koch et al. 
1992).  
 
In vitro studies have shown a link between Hcy and MCP-1. Expression and secretion of 
MCP-1 and IL-8 are upregulated in human aortic endothelial cells following treatment 
with pathophysiological concentrations of Hcy, thereby altering endothelial cell function 
(Poddar et al. 2001). Recently, it has been shown that chronic “low-folate stress” 
increases MCP-1 synthesis in EA.hy 926 endothelial cells; cells grown in low folate 
culture medium express MCP-1 mRNA and protein at higher concentrations than those 
grown in high folate medium, independent of Hcy (Brown et al. 2006). 
 
Several conditions associated with a high Hcy/low folate phenotype may have shared 
aspects of their underlying etiologies, such as changes in inflammatory mediators. In a 
study of the relationship between MCP-1 and Hcy in women with SLE and matched 
controls, MCP-1 concentrations were higher in patients, and were positively correlated 
with tHcy (Brown et al. 2007). In a subsequent pilot study (Lu et al. 2008), non-
significant trends towards associations between MCP-1 concentrations and both 
folate/Hcy phenotype and MTHFR 677C>T genotype were observed in pre-menopausal 
Caucasian women. That MCP-1 is also affected by age, sex, race, body mass index (BMI) 
and smoking status has variously been reported for the above studies and by others 
(Bielinski et al. 2007, McDermott et al. 2005). To date, there have been no studies of 
sufficient size to determine whether folate and MTHFR 677C>T genotype are significant 
determinants of MCP-1 concentrations in young, healthy males and females. 
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The study population presented here comprises healthy females and males between the 
ages of 20 and 26 years, in which folate/Hcy phenotype has been shown to be influenced 
by different genetic and lifestyle factors that act in a sex-specific manner (Stanislawska-
Sachadyn et al. 2008b). This study population is therefore ideal for testing the hypothesis 
that there are biologically significant positive associations between MCP-1 and tHcy 
concentrations, and negative associations between MCP-1 and folate concentrations, and 
to assess whether such associations are restricted to, or more prominent in, reproductive-
aged females compared to males of the same age group. The implications of the findings 
for elucidating etiologic aspects of autoimmune diseases, which are more common in 
women than men, are discussed. 
 
2.3 Materials and Methods 
2.3.1 Study subjects 
Study subjects were enrolled in the Young Hearts Project (YH), an ongoing longitudinal 
study that initially examined the prevalence of coronary risk factors in a sample of young 
people (aged 12 and 15) from Northern Ireland (where FA fortification is not mandated) 
recruited between 1989 and 1990. All of the subjects in the original cohort were invited 
back to participate in a hospital-based screening visit between 1997 and 1999, when the 
subjects were between the ages of 20 and 26 years, at which time the blood samples 
(obtained after an overnight fast) and demographic/lifestyle data used in this report were 
collected. The participation rate for this phase of the study was 48.2%, with 250 males 
and 239 females. Compared to non-respondents, these subjects tended to be from families 
with higher socioeconomic status and to have lower BMI at the baseline examination 
17 
 
(Boreham et al. 1999).  Subjects were broadly classified as smokers or non-smokers, 
based on self-report at the time of follow-up. Ethical approvals were granted by the 
Research Ethics Committee of Queen’s University Belfast, and all subjects provided 
written informed consent. 
 
There were 57 MTHFR 677TT homozygotes for whom serum samples were available. 
The more numerous MTHFR 677CC homozygotes and CT heterozygotes were matched 
to the TT homozygotes by both sex and smoking status. Within each resulting genotype-
phenotype sub-class, subjects were randomly selected using SAS version 9.1 to generate 
sets of 57 CC and 57 CT subjects, each of which had the same distribution of male and 
female smokers and non-smokers as in the TT set. 
 
2.3.2 Biochemical parameters 
Blood samples were obtained from fasted subjects for determination of biochemical 
parameters. tHcy concentrations were measured using high performance liquid 
chromatography (Ubbink, Hayward Vermaak & Bissbort 1991). Serum folate 
concentrations were assessed using time-resolved immunofluorescence on an AutoDelfia 
analyzer (Kluijtmans et al. 2003)(Kluijtmans et al. 2003). RBC folates were determined 
using a microbiological assay (Molloy, Scott 1997).  MCP-1 concentrations were 
measured in archived serum samples using a human MCP-1 ELISA kit (BD Biosciences) 
according to the manufacturer’s instructions. 
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2.3.3 Genotyping 
The DNA extraction method and MTHFR 677C>T genotypes have previously been 
reported (Kluijtmans et al. 2003). 
CCL-2 (-2518) A>G genotypes were generated from the archived DNA samples using a 
previously reported method (Lu et al. 2008). Briefly, genomic DNA was mixed with 0.5 
μM each of forward (5’-TTCTTGACAGAGCAGAAGTGG-3’) and reverse (5’-
GCCTTTGCATATATCAGACAGTA-3’) primers, 50 nM each of “A”-allele probe (5’-
6FAM-AGACAGCTATCACTT-3’-MGBNFQ) and “G”-allele probe (5’-VIC-
AGACAGCTGTCACTTTC-3’-MGBNFQ) in 20 μL Taqman master mix (Applied 
Biosystems). PCR was performed with an initial incubation at 95oC for 10 min, 60 cycles 
of denaturation at 95oC for 15 sec, and the extension/5’ nuclease step at 57oC for 30 sec. 
 
2.3.4 Statistical analyses 
Statistical analyses were performed using SAS version 9.1 with type I error rate set at 
0.05. MCP-1 concentration was log-transformed to better approximate normality in all 
analyses. Differences between subsets of the study subjects (e.g. males and females) in 
the distribution of categorical variables were assessed using chi-square analysis or the 
Fisher’s exact test, and differences in continuous variables were assessed using the t-test.  
Simple linear regression analyses were performed with log MCP-1 concentration as the 
outcome measure. Results of log MCP-1 analyses were back-transformed to report results 
in original measurement units (pg/mL). 
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2.4 Results 
2.4.1 Study Subjects 
A total of 75 men and 96 women were selected from the “Young Hearts” population 
(Boreham et al. 1999) for this study. They comprised equal numbers of each MTHFR 
677C>T genotype class (i.e. CC, CT, and TT), matched by sex and smoking status. The 
mean age for men was 22.4 and for women it was 23.1 years. The mean MCP-1 
concentration in males was 319.7 pg/mL and in females was 261.1 pg/mL (p=0.004). As 
MCP-1 concentrations and several other variables differed significantly between males 
and females, all analyses were performed separately by sex. The characteristics of the 
study subjects are summarized in Table 2-1.  
 
Table 2-1  Subject Characteristics, Biochemical Phenotypes, and Genotypes 
 
Variables 
Sex  
p-value Males (N=75) Females (N=96) 
Age1 22.4±1.6 (75) 23.1±1.6 (96) 0.014 
BMI (kg/m2) 1 24.0 ± 3.3 (75) 24.0 ± 4.3 (95) 0.904 
Vitamins2    
   Yes 58 (77.3) 73 (76.0)  
   No 17 (22.7) 23 (24.0) 0.865 
Alcohol2    
   No 13 (17.3) 22 (23.2)  
   Yes 62 (82.7) 73 (76.8) 0.455 
Cigarettes2    
   No 50 (67.6) 48 (50.0)  
   Yes 24 (32.4) 48 (50.0) 0.065 
MCP-1 (pg/mL)3 319.7 [265.3-371.8] (75) 261.1 [210.5-315.8] (96) <0.0014 
Hcy (μmol/L)1 11.8±7.7 (75) 10.5±5.5 (94) 0.244 
Serum folate (nmol/L)1 14.3±7.9 (71) 15.1±10.5 (91) 0.564 
Red cell folate (nmol/L)1 321.0±140.5 (70) 272.4±156.1 (93) 0.044 
CCL-2 (-2518)A>G2    
   AA 39 (52.7) 46 (49.5) 0.706 
   AG 31 (41.9) 38 (40.9)  
   GG 4 (5.4) 9 (9.7)  
1Mean ± SD (n) 
2Count (percentage) 
3 Mean [Inter-quartile range] (n) 
4p-value by t-test 
5p-value by chi-square 
6p-value by Fisher’s exact test 
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2.4.2 MCP-1 concentrations in relation to age and lifestyle variables 
MCP-1 concentrations were not significantly associated with age, vitamin use, or alcohol 
consumption in either females or males (Table 2-2). MCP-1 was positively associated 
with BMI in females (p= 0.02), but not in males. The BMI variable explained 
approximately 5% of the variation in MCP-1 concentrations in females. Among females, 
smokers had higher MCP-1 concentrations than non-smokers, although this relationship 
did not reach statistical significance (276.9 vs. 246.2 pg/mL, p=0.08). MCP-1 
concentrations were not associated with smoking status in males. 
 
Table 2-2  Proportion of Variation (R2) in MCP-1 Levels Explained by Subject 
Characteristics, Biochemical Phenotypes, and Genotypes, by Sex 
 
 
 
Variables 
Sex 
Males (N=75) Females (N=96) 
Variable 
Coefficient (SE) 
R2 (p-value) Variable 
Coefficient (SE) 
R2 (p-value) 
Subject characteristics     
   Age (years) 0.002 (0.008) 0.0007 (0.82) 0.001 (0.009) 0.0002 (0.90) 
    BMI (kg/m2) -0.002 (0.004) 0.005 (0.54) 0.008 (0.003) 0.06 (0.02) 
   Vitamins (no/yes) -0.05 (0.03) 0.04 (0.08) 0.003 (0.03) 0.0001 (0.93) 
   Cigarettes (no/yes) 0.003 (0.03) 0.0002 (0.92) 0.05 (0.03) 0.03 (0.08) 
   Alcohol (no/yes) -0.02 (0.03) 0.008 (0.44) -0.04 (0.04) 0.01 (0.32) 
Biochemical phenotypes     
   Homocysteine (μmol/L) -0.0006 (0.002) 0.002 (0.70) 0.006 (0.003) 0.06 (0.01) 
   Serum folate (nmol/L) 0.0005 (0.002) 0.001 (0.77) -0.003 (0.001) 0.06 (0.02) 
   RBC folate (nmol/L) 0.00003 
(0.00004) 
0.007 (0.51) -0.00009 
(0.00004) 
0.05 (0.03) 
Genotypes     
   MTHFR 677C>T     
     CT -0.02 (0.03) 0.02 (0.57) 0.06 (0.04) 0.04 (0.14) 
     TT 0.007 (0.03)  0.06 (0.04)  
     T carriers -0.008 (0.03) 0.001 (0.76) 0.06 (0.03) 0.04 (<0.05) 
   CCL-2 (-2518)A>G     
     AG 0.01 (0.03) 0.004 (0.88) 0.01 (0.03) 0.01 (0.64) 
     GG 0.008 (0.06)  0.05 (0.05)  
     G carriers 0.009 (0.02) 0.002 (0.71) 0.02 (0.03) 0.006 (0.45) 
 
 
2.4.3 MCP-1 concentrations in relation to biochemical phenotypes 
In females, tHcy concentrations were positively associated with MCP-1 (p= 0.01) and 
explained approximately 6% of the variation in MCP-1 concentration. Further, among 
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females, MCP-1 concentrations were inversely associated with serum folate (p=0.02) and 
RBC folate (0.03). Serum folate and RBC folate explained approximately 6% and 5% of 
the variation in serum MCP-1 concentrations, respectively. No such associations between 
MCP-1 concentrations and tHcy, serum folate, or RBC folate were observed in males. 
 
2.4.4 MCP-1 concentrations in relation to genotypes 
Among females, MTHFR 677T carriers had significantly higher MCP-1 concentrations 
than CC homozygotes (273.8 vs. 237.5 pg/mL, p<0.05); the CT and TT genotype classes 
had similar concentrations (273.7 and 273.9 pg/mL, respectively).  In contrast, among 
males, MTHFR 677T carriers had MCP-1 concentrations that were similar to those 
observed in CC homozygotes (317.7 vs. 323.6 pg/mL, p=0.76) (Tables 2 and 3). MCP-1 
was not associated with CCL-2 (-2518)A>G genotypes in either females or males (Table 
2-3).  
 
Table 2-3 Mean MCP-1 Level by Sex and Other Covariates 
 
 
Variables 
Mean MCP-1 Level (pg/mL)  
[Inter-quartile range] 
Males p-value1 Females p-value1 
Cigarettes     
   No 317.0 [258.1-366.0] 0.92 246.2 [206.2-293.6] 0.08 
   Yes 319.0 [279.8-380.8]  276.9 [216.5-343.9]  
MTHFR 677C>T     
   CC 323.6 [296.2-371.8] 0.57 237.5 [203.9-282.9] 0.14 
   CT 306.8 [257.3-349.7]  273.7 [214.0-331.0]  
   TT 329.0 [258.1-394.2]  273.9 [226.8-308.0]  
   T carriers 317.7 [257.3-366.0] 0.76 273.8 [216.2-326.1] <0.05 
CCL-2 (-2518)A>G     
   AA 317.8 [279.9-364.9] 0.88 253.9 [204.5-308.9] 0.64 
   AG 325.0 [253.1-398.4]  263.1 [211.9-312.8]  
   GG 321.1 [256.6-410.6]  291.1 [251.7-321.7]  
   G carriers 324.6 [253.1-398.4] 0.71 267.4 [215.9-321.7] 0.45 
1p-values taken from relevant linear regressions in Table 2 
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2.5 Discussion 
Altered folate/Hcy metabolism and increased MCP-1 concentrations are both potentially 
pathologic aspects of many human diseases in which inflammation is an etiologic feature. 
A study of women with SLE and matched controls found that in this auto-immune 
disease, characterized by systemic inflammation, MCP-1 concentration is positively 
associated with tHcy concentration (Brown et al. 2007). In a recent small pilot study in 
healthy, pre-menopausal women (Lu et al. 2008), a trend towards a reciprocal 
relationship between MCP-1 concentration and folate concentration was observed, 
though the results reported did not reach statistical significance. 
 
The above in vivo observations in healthy and inflamed subjects have their corollary in in 
vitro studies that demonstrate a link between chronic low folate stress and increased 
MCP-1 synthesis (Brown et al. 2006, Lu et al. 2009). In the absence of any inflammatory 
stimulus, cells grown in low folate culture medium have higher MCP-1 mRNA and 
protein expression than folate-replete cells (Brown et al. 2006). This finding appears to 
be mediated through a stress response driven, at least in part, by increased cellular levels 
of p38 acting on the CCL-2 promoter (Lu et al. 2009). In the presence of an inflammatory 
stimulus, such as the cytokine TNF-α, MCP-1 transcription is massively induced (more 
than 15-fold) via an NF-κB-dependent mechanism; however, the transcriptional and 
synthetic advantage of MCP-1 seen in the absence of cytokine stimulation is retained. 
Taken together, these in vitro observations suggest that, in vivo, individuals with a low 
folate, high Hcy phenotype would have elevated MCP-1 concentrations relative to their 
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folate-replete peers, regardless of health status. The results, reported here, support this 
hypothesis in a population of healthy, young women, but not in males. 
 
Given the known responsiveness of the CCL-2 gene to overt inflammatory stimuli, it 
might be expected that factors that have been linked to sub-clinical inflammation would 
also be associated with elevated MCP-1 concentrations. This study supports such an 
association between smoking and high MCP-1 concentrations in women only. In 
addition, elevated BMI, which is also often accompanied by sub-clinical inflammation, 
was associated with increased MCP-1 concentrations in women. 
 
There was no association between CCL-2 (-2518)A>G genotype and MCP-1 
concentrations in this study population. The CCL-2 (-2518)A>G polymorphism, located 
in the promoter region of the gene that encodes MCP-1, modifies the degree to which 
MCP-1 expression is induced by proinflammatory stimuli (Rovin, Lu & Saxena 1999). 
The (-2518)G allele is associated with increased MCP-1 transcription mediated by 
interleukin-1 (IL-1), and consequently with higher circulating concentrations of MCP-1 
protein (Rovin, Lu & Saxena 1999, Fenoglio et al. 2004). As the subjects in the present 
study were healthy and without known overt transient or chronic inflammatory 
conditions, this result is not surprising. 
 
The relationships observed between MCP-1 and folate, Hcy, and MTHFR 677C>T 
genotype in females are consistent with the published in vitro studies. HHcy is associated 
with an increased secretion of chemokines, including MCP-1, that can be reversed by 
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low-dose FA treatment (Wang et al. 2005). This effect is compatible with mechanisms 
involving the Hcy-lowering effects of FA, the augmentation of cellular folate status per 
se, or a combination of each. We hypothesized that a relationship would exist between 
MTHFR 677C>T genotype and MCP-1 concentration based on (i) the effect that the 
functional polymorphism of the enzyme specified by the T allele has on tHcy and folate 
derivative distribution, and (ii) the positive and reciprocal quantitative relationships that 
these biochemical variables have with MCP-1. Specifically, as T carriers have altered 
folate and tHcy concentrations, we speculated that they would have higher MCP-1 
concentrations as was reported here for female T allele carriers.  
 
In this study, the association between folate/Hcy phenotype and MCP-1 concentrations is 
restricted to females. Previous studies on this population have shown that tHcy and folate 
concentrations are influenced by different genotypic and phenotypic factors in a sex-
specific manner (Stanislawska-Sachadyn et al. 2008b), so the absence of analogous 
findings regarding folate/Hcy phenotype and MCP-1 in males has precedent. This 
observation suggests that the mechanistic link between folate/Hcy metabolism and MCP-
1 synthesis might involve sex hormones. Whether or not this is the case, the novel 
associations observed here between folate, Hcy and MCP-1 may have implications for 
understanding the complex etiology of auto-immune inflammatory diseases, such as SLE 
and RA, that are more common in females than in males. These findings could also have 
important implications for pregnancy-related pathologies, including folate-preventable 
birth defects such as spina bifida. MCP-1 is produced by endometrial tissue in very early 
25 
 
pregnancy (Caballero-Campo et al. 2002), and the CCL-2-2518A>G polymorphism has 
been associated with the risk of spina bifida (Jensen et al. 2006).  
 
In conclusion, several pathologies associated with altered folate/Hcy metabolism are 
inflammatory in nature, including SLE, RA, and cardiovascular disease. The associations 
of serum folate, RBC folate, and MTHFR 677C>T genotype with MCP-1 strongly 
suggest that MCP-1-mediated inflammation may be a causative or contributing factor to 
pathologies in which folate/Hcy dysregulation is an underlying feature. 
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Chapter 3 
Folate Phenotype, Genotype, Inflammation and Disease Activity  
in Patients Treated with Methotrexate 
 
3.1 Abstract 
Elevated Hcy is associated with several inflammatory diseases, including RA. Patients 
with RA are predisposed to atherosclerosis. MTX is an antifolate medication that is used 
at low doses as a disease modifying anti-rheumatic drug (DMARD) for the treatment of 
RA and other inflammatory diseases. MCP-1 and IL-8 are inflammatory proteins that 
have been shown to be up-regulated in cell culture models after treatment with MTX. 
This study was designed to explore the effect of antifolate drug treatment on response to 
MTX therapy, as well as the effect of genetic polymorphisms in folate-metabolizing 
enzymes and their effects on biochemical parameters. It also examined whether genetic 
polymorphisms in folate-metabolizing enzymes can predict which patients will benefit 
most from MTX treatment and which are most likely to suffer from toxicities. Total RBC 
folate and RBC 5-MTHF decreased from baseline to follow up, while other folate 
derivatives (RBC THF and RBC 5,10-MTHF) increased. Measures of clinical state 
improved from baseline to follow up. Individuals with the MTHFR 677TT genotype 
responded differently than MTHFR CC or CT subjects for many of the variables 
examined. MCP-1 concentration increased from baseline to follow up, and the absolute 
change and percent change correlated with the changes in IL-8 concentration. 
 
 
27 
 
3.2 Introduction 
HHcy, usually associated with low folate concentration, is a condition defined by 
elevated levels of Hcy in the blood and is a known risk factor for several diseases, 
including RA (Wallberg-Jonsson et al. 2002, Chiang et al. 2003). RA is a systemic 
inflammatory disease that affects synovial joints.  
 
MTX is an antifolate medication that is used at low doses as a DMARD for the treatment 
of RA and other inflammatory diseases. MTX enters the cell through RFC-1 and is then 
polyglutamated, allowing it to accumulate (Chabner et al. 1985). It is one of the most 
commonly used drugs for the treatment of RA (Weinblatt et al. 1985, Kremer, Lee 1986). 
MTX primarily inhibits DHFR. DHFR is an enzyme that reduces folic acid (FA), the 
synthetic form of folate obtained from fortified foods and supplements in pill form, to 
dihydrofolate (DHF) and also reduces DHF to THF. MTX also inhibits TYMS, which 
converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate 
(dTMP). 
 
Functional polymorphisms in several of the enzymes can affect the distribution of folate 
intermediates in the pathway and lead to increased levels of Hcy. The most widely 
studied SNP in the folate metabolic pathway is the MTHFR 677C>T polymorphism. This 
transition causes an alanine to valine substitution at residue 222 in the catalytic domain of 
the enzyme, forming a thermolabile variant of the enzyme that is less efficient at 
converting 5,10-MeTHF to 5-MTHF. The MTHFR 1298A>C polymorphism also results 
in decreased enzyme activity (Weisberg et al. 1998). 
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There are two polymorphisms of interest in TYMS. One is a variable number of tandem 
repeats (VNTR) in the 5’ untranslated region (UTR), which is a 28 base pair (bp) tandem-
repeat element most commonly with 2 or 3 copies (Horie et al. 1995). The 3R allele has 
been associated with increased protein concentrations (Kawakami et al. 1999). The other 
polymorphism is TYMS 1494del6, a 6 bp insertion/deletion polymorphism in the 3’ UTR; 
a study has suggested that this polymorphism decreases mRNA stability and translation 
(Mandola et al. 2004). 
 
DHFR c.86 + 60_78 is a 19bp insertion/deletion polymorphism within the first intron of 
DHFR. The deletion removes a possible Sp1 transcription factor binding site, which may 
affect transcriptional regulation (Johnson et al. 2004). In a study of young adults from 
Northern Ireland, women with the del/del genotype had increased serum and RBC folate 
concentrations compared to ins carriers (Stanislawska-Sachadyn et al. 2008a). 
 
RA patients are predisposed to artherosclerosis, a disease involving thickening and 
hardening of the artery wall (Szekanecz et al. 2007, Shoenfeld et al. 2005). Individuals 
with RA are at increased risk for morbidity and mortality from cardiovascular disease 
(Kaplan 2006). Chemokines promote directed migration of inflammatory cells, and some 
are involved in the pathogenesis of atherosclerosis. Accumulation of oxidized LDL in the 
subendothelium causes local cells to produce MCP-1, leading to the migration of 
monocytes across the endothelium. Deposition of lipids within these cells leads to the 
formation and enlargement of atherosclerotic lesions (Harrington 2000). MCP-1 is 
chemokine that is encoded by the CCL2 gene (Graves, Jiang 1995). This chemokine has 
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been shown to be highly expressed in serum, synovial tissue, and synovial fluid in 
patients with RA (Koch et al. 1992). 
 
IL-8 is a chemokine produced by macrophages that functions as a chemoattractant. In 
pathological conditions, it has been shown to be produced excessively by fibroblasts, 
macrophages and neutrophils (Huebner, Seifer & Kraus 2007). Additionally, 
synoviocytes stimulated with pro-inflammatory molecules have been shown to release 
MCP-1 and IL-8 (Loetscher et al. 1994). IL-8 has also been found to be elevated in the 
synovium of RA patients compared to subjects with osteoarthritis and asymptomatic 
donor controls (Kokebie et al. 2011). 
 
A cell culture model using the EA.hy 926 endothelial cell line, adapted to growth under 
low folate conditions in Medium 199, showed that chronic “low-folate stress” increased 
MCP-1 synthesis in EA.hy 926 cells. Cells grown in low folate culture medium expressed 
MCP-1 mRNA and protein at higher concentrations than those grown in high folate 
medium, independent of Hcy (Brown et al. 2006). It has also been reported that 
expression and secretion of MCP-1 and IL-8 are up-regulated in human aortic endothelial 
cells following treatment with pathophysiological concentrations of Hcy (Poddar et al. 
2001). Results from ongoing studies in our laboratory indicate that MTX increases 
synthesis of a range of inflammatory mediators, including IL-8 and complement 
component 3 (C3), in EA.hy 926 endothelial cells (unpublished). 
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This study was designed to explore the effect of antifolate drug treatment on disease 
state, as well as the effect of genetic polymorphisms in folate-metabolizing enzymes and 
their effects on biochemical parameters during treatment. This study also examined the 
relationship between the concentrations of MCP-1 and IL-8, two inflammatory proteins, 
and their relationship with clinical status.  
 
3.3 Materials and Methods 
3.3.1 Subject Recruitment 
Two hundred and thirty eight subjects who fulfilled the 1987 American College of 
Rheumatology revised criteria (Arnett et al. 1988)were recruited under the direction of 
Dr. Joan Von Feldt. This observational study was designed to evaluate the effect of 
treatment with MTX in subjects who were considered good candidates for this therapy. 
This study was approved by the University of Pennsylvania Institutional Review Board 
and all subjects provided written informed consent. 
 
At the first visit (baseline) visit, blood samples for biochemical and genetic studies were 
obtained from MTX-naïve subjects, and a health evaluation was performed for physician 
global assessment (PGA) score and American Rheumatism Association (ARA) functional 
classification. Questionnaires were obtained to gather demographic and lifestyle 
information, including age, race, current and previous tobacco and alcohol use, height, 
weight, body mass index (BMI), family medical history, medications (including vitamins 
and history of MTX treatment), and other medical conditions. Subjects returned for a 
second visit (follow-up) visit at least 18 weeks after the baseline visit to provide another 
31 
 
blood sample, fill out a questionnaire, and undergo a second health evaluation. After 18 
weeks on drug, enough time had passed that all of the red blood cells had turned over and 
the RBC folates concentration is representative of the time period since MTX therapy 
was started. A subset of the data collected was used for analysis in this study. One 
hundred and forty eight patients attended both the baseline and follow-up visits.  
 
For the purposes of this study, twenty five different adverse reactions were defined. In 
addition, untoward symptoms reported by patients that do not fall within one of these 
twenty five define categories were recorded as “other”. Severe toxicities, or those that are 
considered to be of medical concern that would lead to careful medical observation, 
decrease in drug dose or discontinuation of drug include pneumonitis, hemorrhagic 
enteritis, and bone marrow depression. Attributable toxicities, or those considered likely 
to be caused by MTX treatment include the above severe toxicities plus leucopenia, 
thrombocytopenia, abnormal mean corpuscle volume (MCV), abnormal alanine 
transaminase/aspartate transaminase/alkaline phosphatase (ALP/ALT/AST), other 
abnormal liver function tests (LFTs), elevated Hcy, photosensitivity/hyperpigmentation, 
urticaria/puritis, alopecia, and mucositis. 
 
3.3.2 Genotyping 
DNA was extracted from whole blood using QIAamp DNA Mini Kits (Qiagen, Santa 
Clarita, CA). For genotyping of MTHFR 677C>T, MTHFR 1298 A>C, and CCL2 -
2518A>G, TaqMan genotyping methods were used on a DNA Engine Opticon 2 
continuous fluorescence detection system (Bio-Rad, Hercules, CA). 
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PCR amplifications took place in 20 μl volumes containing 20 ng genomic DNA, 
forward and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions 
consisted of an initial incubation at 50°C for 2 minutes, 95°C for 10 minutes, and 50 
cycles of assay specific temperatures for denaturation and extension. Dual fluorescence 
was measured at the end of each cycle. Genotype interpretations were performed with 
Opticon Monitor Analysis software, version 2.02 (Bio-Rad). 
 
Genotyping of TYMS 1494del6, TYMS 5’ VNTR, and DHFR c.86+60_78 were performed 
using size difference PCR methods. PCR amplifications were performed using 50 ng 
genomic DNA, forward and reverse primers, dNTPs, 10x PCR buffer (Applied 
Biosystems), and AmpliTaq DNA polymerase (Applied Biosystems) in a total volume of 
25 ul. PCR products were separated on 3% agarose gels run at 140V for 45 minutes. Gels 
were then stained with ethidium bromide. DNA isolation and MTHFR 677C>T 
genotyping assays were performed by Dr. Anna Stanislawska-Sachadyn. 
 
3.3.3 Biochemical Phenotyping 
Stable isotope dilution liquid chromatography multiple reaction monitoring mass 
spectrometry (LC-MRM/MS) methods were employed to measure select folate 
derivatives (5-MTHF, THF, and 5,10-MTHF), FA, and Hcy in RBCs and plasma using 
using methods previously described by Stefanie Khartulyari and Dr. Yuehua Huang in 
Dr. Ian Blair’s laboratory (Huang et al. 2007, Huang et al. 2008). 
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Total RBC folate, as defined in this study, is sum of key analytes that represent all of the 
folate in the RBCs. The method used for folate measurement drives all of the folate 
derivatives into one of three forms that are important in different biochemical domains of 
the pathway, and are useful in identifying folate phenotypes. 
 
The flux of folates through the pathway is determined to a certain extent by the provision 
of 5-MTHF and its dynamic conversion to THF. A disruption or alteration of the pathway 
would potentially alter this ratio, and it would be expected that genotype might underpin 
this relationship. Thus, the ratio of 5-MTHF:THF was calculated for analysis in this 
study. 
 
IL-8 protein levels were measured using an IL-8 ELISA kit (BD Biosciences, San Jose, 
CA). MCP-1 protein levels were measured by Dr. Zhi-Yong Lu using an MCP-1 ELISA 
kit (BD Biosciences, San Jose, CA).  
 
C-reactive protein (CRP) and Westergren erythrocyte sedimentation rates (ESR) was 
measured in the William Pepper Laboratory of Clinical Medicine at the Hospital of the 
University of Pennsylvania (HUP) using VITROS MicroSlides (Ortho-Clinical 
Diagnostics, Rochester, NY). 
 
3.3.4 Statistical analysis 
All statistical tests were performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC). 
Measurement of variables at baseline and follow-up included only the individuals who 
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had both baseline and follow-up measurements for the specific variable being evaluated. 
Differences between phenotypic variables at baseline and follow-up were measured using 
t test. Parametric analysis of differences based on genetic polymorphisms was done using 
general linear model (GLM) tests; in the case of certain variables analyzed in the context 
of MTHFR 677C>T genotype, results were not as expected using the parametric tests, 
and non-parametric analysis of variance (ANOVA) was used. MCP-1 and IL-8 
concentrations were ranked and divided into tertiles, which were then used to stratify 
PGA at baseline and follow up. This analysis was also done using ANOVA methods. 
CRP values reported by the clinical laboratory as <0.3 were given values of 0.3 and 
vitamin B12 values reported as >1000 were given values of 1000 in order to analyze the 
data. 
 
3.4 Results 
One hundred and nineteen Caucasians participated in the baseline and follow-up visits 
and these constitute the study population under investigation. For evaluation of individual 
demographic and phenotypic data, only individuals for whom data were available for 
both baseline and follow-up were included for the analysis of that variable. Table 3-1 
shows the subject characteristics and biochemical phenotypes at baseline and follow-up, 
and lists the differences between variables of these two time points.  
 
3.4.1 Clinical and Biochemical Phenotypes 
The median age for individuals in this study was 55.5 at baseline. Median BMI was 30.64 
at baseline and 30.68 at the follow-up visit.  
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Vitamin B12 concentration increased from 552.38 nmol/L at baseline to 576.79 nmol/L at 
follow up (p=0.07). Plasma FA also increased, from 7.51 nmol/L at baseline to 36.20 
nmol/L at follow up (p<0.0001). When starting MTX treatment, patients are routinely 
counseled to take either over-the-counter or prescription FA supplements; the above 
increase in FA indicates that many subjects were compliant with the recommendation. 
Nevertheless, plasma 5-MTHF decreased from 54.60 to 40.00 nmol/L (p=0.0009) from 
baseline to follow up. RBC total folate decreased from 1385.43 nmol/L to 1232.08 
nmol/L (p=0.001). This decrease in total RBC folate was driven by the decrease in RBC 
5-MTHF concentration from 1279.00 to 1115.02 nmol/L (p=0.0005); the other two folate 
analytes, that together with 5-MTHF constitute the components of total RBC folate, both 
increased.  RBC 5,10-MTHF increased from 26.01 to 30.01 nmol/L (p=0.0007) and RBC 
THF increased from 87.79 to 92.04 nmol/L (p=0.49); consequently, the ratio of 5-
MTHF:THF decreased from 41.08 to 33.77 nmol/L (p=0.03). No appreciable difference 
was measured in tHcy concentration from baseline to follow up (10.61 and 10.41 μmol/L, 
respectively, p=0.48). Due to the design of this study, the subjects were not fasting when 
the sample was obtained for tHcy measurement, which may explain why there was no 
measurable difference in tHcy between the two time points. 
 
PGA, determined using a visual analog scale of 1-100, was 45.52 at baseline and 27.99 at 
follow up (p<0.0001); ARA class (1=completely able to do usual activities; 2= limited 
avocational activities; 3= limited vocational and avocational activities; 4: limited 
vocational, avocational and usual activities) was 2.05 at baseline and 1.76 at follow up 
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(p<0.0001). Both PGA and ARA class are measures of disease state, and the decrease in 
these values indicates that the clinical status of the population as a whole improved.  
 
MCP-1 concentration increased from baseline to follow up, from 375.93 pg/mL to 423.95 
pg/mL (p=0.01). IL-8 concentration was 10.93 pg/mL at baseline and 10.33 pg/mL at 
follow-up (p=0.64).
Table 3-1 Subject Characteristics and Biochemical Phenotypes 
 Baseline Follow up Difference   
Variable Mean   SD Median Mean SD Median Mean SD Median n p1 
Age 55.7  55.5 56.3  56    118  
BMI (kg/m2) 30.64  7.13 28.90 30.68 6.95 29.50 0.03 2.41 0 109 0.88 
            
Hcy (μmol/L) 10.61  3.51 9.65 10.41 2.58 10.20 -0.21 3.09 -0.30 112 0.48 
Plasma 5-MTHF (nmol/L) 54.6  31.10 46.40 40.00 32.27 35.40 -14.66 45.59 -13.55 112 0.0009 
RBC total folate (nmol/L) 1385.43  585.18 1282.05 1232.08 545.10 1114.70 -153.35 481.98 -120.20 108 0.001 
RBC 5-MTHF (nmol/L) 1278.00  580.85 1149.20 1115.02 531.69 1039.75 -162.98 471.49 -142.50 108 0.0005 
RBC THF (nmol/L) 87.78  180.08 29.95 92.04 171.16 36.55 4.25 64.48 4.7 108 0.49 
RBC 5,10-MTHF (nmol/L) 26.01 44.77 11.58 30.02 50.98 12.57 4.01 15.06 0.66 108 0.007 
Ratio 5-MTHF:THF 41.08  22.05 41.34 33.77 35.53 29.75 -7.31 35.34 -9.91 108 0.03 
Plasma FA 7.51  27.29 0 36.20 63.88 10.95 28.68 52.65 5.65 112 <0.0001 
B12 552.38  255.91 521.00 576.79 258.39 599.00 24.41 137.40 10.00 105 0.07 
            
PGA score 45.52  20.63 42.50 27.29 15.63 27.00 -18.23 24.85 -12.00 108 <0.0001 
ARA class 2.05  0.71 2.00 1.76 0.63 2.00 -0.29 0.70 0 107 <0.0001 
CRP 1.38  2.30 0.70 1.11 2.01 0.60 -0.27 2.00 -0.10 108 0.16 
            
MCP-1 (pg/mL) 375.93  217.86 329.50 423.95 236.95 386.50 48.02 197.67 42.50 118 0.01 
IL-8 (pg/mL) 10.93  12.76 7.90 10.33 9.27 7.56 -0.59 13.73 -0.39 118 0.64 
1p-value by t-test 
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3.4.2 Clinical and Biochemical Variables in Relation to Genotypes  
Polymorphisms in several genes in the folate metabolic pathway (MTHFR 677C>T, 
MTHFR 1298A>C, DHFR  c.86+60_78, TYMS 5’  VNTR, TYMS 1494del6, CCL2 -
2518A>G) were examined in this study. Distributions of genotypes distributions are 
given in Table 3-2. All genotypes, with the exception of MTHFR 1298 A>C, were in 
Hardy-Weinberg equilibrium. The relationship between the above polymorphic variants 
and clinical and biochemical differences in variables were examined. Statistical tests 
were performed to examine the relationship between each individual genotype from 
baseline to follow-up visits. Tests were also performed to examine differences among 
genotypes for baseline and follow-up visits and for the differences between them. 
 
Table 3-2  Genotype distributions. 
 
 
 
  n (%) 
MTHFR 677C>T CC 55 (46.2) 
 CT 53 (44.5) 
 TT 11 (9.2) 
MTHFR 1298A>C AA 50 (42.0) 
 AC 62 (52.1) 
 CC 7   (5.9) 
DHFR  
c.86+60_78 
del/del 24 (20.2) 
 ins/del 63 (52.9) 
 ins/ins 32 (26.9) 
TYMS 5’  VNTR 2R/2R 25 (21.0) 
 2R/3R 57 (47.9) 
 3R/3R 36 (30.3)  
 2R/4R 1   (0.8) 
TYMS 1494del6 del/del 15 (12.6) 
 ins/del 48 (40.3) 
 ins/ins 56 (47.1) 
CCL2 -2518A>G AA 60 (50.1) 
 AG 47 (39.5) 
 GG 12 (10.1) 
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DHFR is the main enzyme in the folate metabolic pathway that is targeted by MTX. 
However, even though it is the main target, the individual DHFR c.86+60_78 genotypes 
had no differential effect on any of the phenotypic variables examined in this study 
(Appendix A Table 2). Thus, it does not appear that DHFR c.86+60_78 genotype impacts 
the outcome of MTX treatment. This result reinforced the rationale for the examining the 
possible influence of the other genetic polymorphisms listed above. 
 
For many of the clinical and biochemical variables examined in this study, individuals 
with the MTHFR 677TT genotype were distinct from MTHFR 677C carriers (CC and 
CT). For example, for both MTHFR 677CC and CT subjects, there was a decrease in total 
RBC folate and RBC 5-MTHF concentrations.  CC decreased from 1286.84 nmol/L to 
1158.19 nmol/L (p<0.0001) and CT decreased from 1496.00 nmol/L to 1261.19 nmol/L 
(p<0.0001). For these genotype classes, this was accompanied by an increase in RBC 
THF concentration, thereby mandating a decrease in the ratio of 5-MTHF:THF. RBC 
THF increased from 28.35 nmol/L to 38.79 nmol/L in CC subjects (p=0.0005), leading to 
a decrease in the ratio of 5-MTHF:THF from 47.72 to 40.44 (p=0.30). In CT subjects, 
RBC THF increased from 61.22 to 64.87 nmol/L (p=0.56), leading to an decrease in the 
ratio from 42.01 to 32.87 (p=0.0003). Furthermore, MCP-1 concentration increased (from 
370.19 to 403.69 pg/mL for CC and from 386.57 to 474.13 pg/mL for CT) and PGA 
score decreased significantly (from 46.86 to 27.40 and from 45.20 to 25.37, respectively. 
In contrast, for MTHFR 677TT homozygotes, RBC total folate and 5-MTHF were both 
increased (1344.98 to 1461.79 nmol/L and 706.80 to 834.83 nmol/L, respectively) and 
RBC THF was decreased (from 512.49 to 488.67 nmol/L).  For this genotype class, these 
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changes mandated a slight, but not significant, increase in the ratio of 5-MTHF:THF from 
125.69 to 138.29. In addition, MTHFR 677TT homozygotes experienced a decrease in 
MCP-1 concentration (352.91 pg/mL at baseline to 281.64 pg/mL at follow-up). PGA 
score decreased, as it did in the CC and CT subjects, although to a much less significant 
degree (from 39.78 to 37.11 at follow-up). Taken together, these results indicated distinct 
responses to MTX depending on MTHFR 677C>T genotype class. Some of these are 
statistically significant and some are quantitatively striking and may not reach statistical 
significance, possibly due to low numbers of MTHFR 677TT homozygotes. 
 
Several of the baseline genotypes differed between the three MTHFR 677C>T genotypes 
(Table 3-3). Specifically, significant differences were observed for vitamin B12 (p=0.01), 
BMI (p=0.02) and CRP (p=0.02) and plasma 5-MTHF (p=0.03). In addition, MCP-1 
concentrations at follow-up and the changes in MCP-1 concentration between the 
baseline visit and the follow up visit differed significantly between the above genotype 
classes (p= 0.03 and 0.04, respectively)
1 
Table 3-3 Effects of MTHFR 677C>T genotype on variables at baseline, follow-up and the difference between the time points 
 CC CT TT  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
BMI Baseline 29.53 5.10 29.15 50 30.60 6.86 28.50 49 36.45 13.14 32.95 10 0.02 
Follow up 29.61 5.82 29.85 50 30.85 6.84 29.30 49 35.16 10.80 33.45 10 0.07 
Difference 0.08 2.61 0.15 50 0.26 1.83 0.00 49 -1.29 3.58 -0.25 10 0.18 
p2 .82    .33    .28     
tHcy Baseline 11.00 3.00 11.00 51 9.76 2.48 9.50 51 13.02 7.48 10.35 10 0.01 
(μmol/L) Follow up 10.22 2.51 10.10 51 10.35 2.55 10.00 51 11.65 3.09 11.55 10 0.27 
Difference -0.78 2.19 -0.50 51 0.59 2.97 -0.10 51 -1.37 5.93 0.35 10 0.04 
p2 0.01    0.16    0.48     
Plasma  Baseline 51.70 25.65 49.60 51 61.43 35.86 53.50 51 35.24 19.95 31.40 10 0.03 
5-MTHF Follow up 43.63 43.80 35.60 51 36.77 16.37 35.20 51 37.92 23.67 29.85 10 0.55 
(nmol/L) Difference -8.07 51.76 -11.30 51 -24.65 38.40 -16.50 51 2.68 37.68 2.30 10 0.08 
p2 .27    <0.0001    .83     
RBC Total  Baseline 1286.84 608.64 1133.20 50 1496.55 580.14 1419.40 48 1344.98 418.30 1358.95 10 0.20 
Folate (nmol/L) Follow up 1158.19 556.36 1063.00 50 1261.19 512.08 1147.15 48 1461.79 620.00 1291.50 10 0.24 
Difference -128.66 529.57 -74.30 50 -235.35 375.64 -291.75 48 116.81 614.64 76.65 10 0.10 
p2 0.09    <0.0001    0.56     
RBC 5-MTHF Baseline 1253.16 594.00 1113.30 50 1422.87 537.60 1377.90 48 706.80 321.01 729.15 10 0.0002 
(nmol/L) Follow up 1110.24 546.34 1017.65 50 1178.36 470.60 1067.45 48 834.83 686.02 692.25 10 0.04 
Difference -142.92 524.62 -118.60 50 -244.50 371.25 -303.30 48 128.03 541.21 36.40 10 <0.05 
p2 0.06    <0.0001    0.47     
 
2 
 CC CT TT  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p 
RBC THF Baseline 28.35 14.37 25.90 50 61.22 90.83 32.85 48 512.49 342.79 417.45 10 <0.0001 
(nmol/L) Follow up 38.79 22.56 31.75 50 64.87 78.94 36.55 48 488.67 344.26 470.85 10 <0.0001 
Difference 10.44 19.84 8.10 50 3.65 43.22 3.15 48 -23.82 190.88 -6.20 10 0.31 
p2 0.0005    0.56    0.70     
RBC  Baseline 12.55 3.91 11.00 50 18.98 22.07 11.42 48 127.03 92.72 113.78 10 <0.0001 
5,10-MTHF  Follow up 14.95 7.16 11.89 50 22.90 26.93 12.69 48 139.53 109.45 123.62 10 <0.0001 
(nmol/L) Difference 2.40 6.22 0.50 50 3.92 10.44 0.83 48 12.50 42.68 24.39 10 0.15 
p2 0.009    0.01    0.38     
Ratio  Baseline 47.72 16.83 44.55 50 42.01 21.32 42.98 48 3.41 5.96 1.50 10 <0.0001 
5MTHF:THF Follow up 40.44 46.52 31.70 50 32.87 19.34 30.81 48 4.72 8.72 1.82 10 <0.0001 
Difference -7.28 49.52 -14.79 50 -9.15 16.33 -10.26 48 1.32 3.02 0.19 10 0.0008 
p2 0.30    0.0003    0.20     
Plasma FA  Baseline 10.39 35.45 0.00 51 5.66 19.69 0.00 51 2.31 4.50 0.00 10 0.56 
(nmol/L) Follow up 35.84 75.59 10.70 51 39.91 55.90 12.20 51 19.13 28.85 7.50 10 0.65 
Difference 25.45 53.75 5.30 51 34.25 55.35 7.90 51 16.82 26.95 3.40 10 0.53 
p2 0.001    <0.0001    0.08     
B12 Baseline 525.77 236.90 475.50 48 618.19 254.51 583.00 47 370.80 263.85 282.00 10 0.01 
(pmol/L) Follow up 579.90 266.61 606.00 48 612.11 240.57 656.00 47 395.90 248.17 326.00 10 0.05 
Difference 54.13 134.96 33.50 48 -6.09 139.08 0.00 47 25.10 120.90 17.50 10 0.10 
p2 0.008    0.77    0.53     
 
3 
 CC CT TT  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p 
PGA score Baseline 46.86 24.37 44.00 50 45.20 17.09 43.00 49 39.78 15.83 40.00 9 0.64 
Follow up 27.40 16.09 24.00 50 25.37 15.45 28.00 49 37.11 10.93 35.00 9 0.12 
Difference -19.46 26.86 -13.00 50 -19.84 23.94 -15.00 49 -2.67 10.12 -4.00 9 0.15 
p2 <0.0001    <0.0001    0.45     
ARA class Baseline 1.96 0.70 2.00 50 2.10 0.68 2.00 49 2.25 0.89 2.00 8 0.43 
Follow up 1.68 0.68 2.00 50 1.78 0.51 2.00 49 2.13 0.83 2.00 8 0.17 
Difference -0.28 0.64 0.00 50 -0.33 0.80 0.00 49 -0.13 0.35 0.00 8 0.75 
p2 0.003    0.006    0.35     
CRP Baseline 1.33 1.97 0.70 49 1.06 1.23 0.70 49 3.21 5.48 0.85 10 0.02 
(mg/L) Follow up 1.26 2.79 0.50 49 0.88 1.00 0.60 49 1.51 0.92 1.50 10 0.54 
Difference -0.08 1.68 0.00 49 -0.18 0.91 -0.10 49 -1.70 5.08 0.15 10 0.06 
p2 0.75    0.18    0.32     
MCP-1 Baseline 370.19 198.36 323.00 54 386.57 171.33 359.00 53 352.91 439.06 236.00 11 0.87 
(pg/mL) Follow up 403.69 200.68 372.50 54 474.13 273.59 422.00 53 281.64 127.99 271.00 11 0.03 
Difference 33.50 90.69 28.00 54 87.57 225.75 69.00 53 -71.27 351.42 42.00 11 0.04 
p2 0.009    0.007    0.52     
IL-8 Baseline 12.44 17.66 8.15 54 9.73 5.61 7.93 53 9.26 8.13 6.35 11 0.50 
(pg/mL) Follow up 10.59 11.41 7.02 54 10.29 7.02 7.85 53 9.22 7.64 7.58 11 0.91 
Difference -1.85 18.78 -0.93 54 0.57 7.10 -0.36 53 -0.04 7.73 0.61 11 0.66 
p2 0.47    0.56    0.99     
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype 
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Figure 3-1 Change in variables from baseline to follow up by MTHFR 677C>T 
genotype. A. Total RBC folate, B. PGA score, C. MCP-1 concentration. 
Data presented in these graphs and results of statistical analyses are 
included in Table 3-1. 
0
500
1000
1500
2000
Baseline Follow up
To
ta
l R
BC
 fo
la
te
 (n
m
ol
/L
) 
CC CT TT
0
10
20
30
40
50
Baseline Follow up
PG
A 
sc
or
e 
CC CT TT
0
100
200
300
400
500
Baseline Follow up
M
CP
-1
 (p
g/
m
L)
 
CC CT TT
A 
C 
B 
 45 
 
RBC total folate decreased for individuals with the MTHFR 1298AA or AC genotype 
(Appendix A Table 1), but increased in subjects with the CC genotype (p=0.0006, 0.04 
and 0.63, respectively). A similar relationship was seen with RBC 5-MTHF, which 
decreased in individuals with the AA or AC genotype but increased for individuals with 
the CC genotype (p=0.0004, 0.03 and 0.72). While RBC THF concentration increased for 
all genotypes, the increase in CC was much higher than in AA or AC.  The increase in 
vitamin B12 concentration was also much higher in CC than in AA or AC. MCP-1 
concentration increased in both AA and AC but decreased in CC. 
 
The TYMS 5’ VNTR polymorphism showed no association with any of the variables 
examined (it should be noted, however, that the single individual with a 3R/4R genotype 
experienced an increase in RBC 5-MTHF concentration, in contrast to the trend in other 
genotype classes). (Appendix A Table 3). 
 
The polymorphism associated with the TYMS 3’ UTR did not have a differential effect on 
any of the variables except vitamin B12, which increased in both del/del and ins/ins 
individuals but did not change for ins/del individuals. There were no significant 
differences among the genotypes for any of the variables at baseline, follow-up or the 
difference between the two time points (Appendix A Table 4). 
 
In this study population there was no association between CCL-2 (-2518)A>G genotype 
and MCP-1 concentration (Appendix A Table 5). 
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3.4.3 Toxicities 
Three toxicities were identified at baseline (i.e. prior to MTX therapy). Following 
treatment with MTX, 31 toxicities were reported. That indicates that the change in 
therapeutic regimen was causing individuals to have more side effects. Of these 31, six 
were considered to be attributable to the MTX component of their treatment. None of the 
toxicities reported were considered to be severe. The possible relationship between the 
genetic polymorphism of the folate pathway enzymes and toxicities was assessed. The 
toxicities reported at follow-up were not associated with any particular polymorphism. 
None of the MTHFR 677C>T, MTHFR 1298A>C, TYMS 5’ VNTR, and DHFR 
c.86+60_78 polymorphisms showed any association either with the total number of 
toxicities or the six that were attributable to MTX. The one that did show positive 
association was TYMS 1494del6. This was restricted to those that were attributable and 
was not associated with the totality of the toxicities (i.e. 31) reported at this time point. It 
should be noted, however, that the number of attributable toxicities is somewhat low 
(Appendix A). 
 
3.4.4 Inflammatory Proteins 
The concentrations of the inflammatory proteins MCP-1 and IL-8 were positively 
correlated at the follow-up visit (Table 3.5). At baseline they were also correlated, 
although this did not reach statistical significance. The absolute change and percent 
change in MCP-1 and IL-8 concentrations from baseline to follow up were also 
significantly correlated.  
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Table 3-4  Correlation between MCP-1 and IL-8 concentrations in patients at 
baseline and follow-up and the relationship between change in these 
variables (n=116) 
 Baseline Follow 
up 
Absolute 
change 
Percent 
change 
Pearson Correlation Coefficie
nt: 
p value: 
0.15 
0.10 
0.24 
0.01 
0.24 
0.009 
0.28 
0.003 
 
Both MCP-1 and IL-8 concentrations were ranked by their measurements at baseline and 
grouped into tertiles. PGA at baseline and at follow-up was examined in the context of 
these tertiles. PGA improved for all individuals, regardless of MCP-1 or IL-8 baseline 
tertile.  
 
Individuals who were in the upper tertile of IL-8 concentration had the highest PGA score 
at baseline (54.34 compared to 44.21 for the lowest tertile and 40.18 for the middle 
tertile). This difference was statistically significant (p=0.008). At follow up, the upper, 
lower and middle tertiles had similar PGA scores, with values of 28.69, 25.69 and 26.94, 
respectively (p=0.73). 
 
At baseline, the mean PGA score for the lower, middle and upper MCP-1 tertiles were 
52.88, 44.57, and 39.95, respectively (p=0.01). At the follow up visit, the mean PGA 
scores had decreased to 31.89 for the lowest tertile, 26.89 for the middle tertile, and 22.22 
for the upper tertile (p=0.03).  
 
When MCP-1 concentration was stratified by IL-8 tertile, the concentration at baseline 
was 299.59 pg/mL for lowest tertile, 393.36 pg/mL for the middle tertile and 419.55  
 48 
 
pg/mL for the upper tertile (p=0.38). At follow up, the lowest tertile had a mean MCP-1 
concentration of 377.74 pg/mL, the middle tertile was 439.10 pg/mL and the upper tertile 
was 440.08 pg/mL (p=0.58). 
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Figure 3-2  Change in variables by MCP-1 and IL-8 tertiles. MCP-1 and IL-8 
concentrations were ranked and divided into tertiles. A. PGA score by 
MCP-1 tertile. B. PGA score by IL-8 tertile. C. MCP-1 concentration by 
IL-8 tertile. 
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3.5 Discussion 
 
The individuals in this observational study had been prescribed MTX for treatment of an 
inflammatory condition. At the baseline visit, patients were MTX-naïve, and after at least 
18 weeks on treatment returned for a follow-up. One hundred and nineteen Caucasians 
attended both the baseline and follow up visits and were analyzed in this study. 
 
Treatment with the antifolate drug MTX caused decreases in plasma 5-MTHF, RBC total 
folate, and RBC 5-MTHF from the baseline visit to the follow up visit in this study 
population as a whole. Conversely, RBC THF increased from the baseline visit to the 
follow up visit. In turn, the ratio of 5-MTHF:THF decreased. Interestingly, despite the 
decrease in total folate and 5-MTHF, there was not a measurable change in tHcy 
concentration between the baseline and the follow-up visits. Due to the fact that this was 
an observational study and not designed as an intervention, subjects were not asked to 
fast which is likely why no change in tHcy concentration was detected. 
 
Both PGA and ARA class, measures of disease state, decreased significantly for between 
the two time points for the subjects in this study, demonstrating that this drug was 
effective in improving clinical status for these subjects.  
 
The concentration of MCP-1, an inflammatory protein that is involved in leukocyte 
recruitment, increased. This increase in MCP-1 from baseline to follow-up suggests a 
potentially pro-atherosclerotic effect from MTX treatment.  
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Polymorphisms of several folate pathway enzymes were analyzed in this study. The most 
interesting genetic results were related to MTHFR 677C>T. The TT genotype seemed to 
affect several of the biochemical variables in a different manner than the CC and CT 
genotypes. MTHFR CC and CT subjects had decreased total RBC folate and RBC 5-
MTHF between baseline and follow up visits, with an increase in RBC THF 
concentration, while TT homozygotes had an increase in total RBC folate and RBC 5-
MTHF, accompanied by a decrease in RBC THF. While MCP-1 concentration increased 
in CC and CT subjects, it decreased in TT homozygotes. PGA score did decrease for all 
of the genotype classes, although this decrease was slight and not significant in TT 
subjects, unlike the CC and CT groups which had quantitatively large and statistically 
significant decreases in PGA.  These data suggest that MTHFR 677C>T genotype has 
distinct effects on biochemical and clinical variables associated with MTX treatment. 
 
There were three toxicities reported prior to starting MTX therapy, and 31 were reported 
at the follow-up visit. Prior to analysis, toxicities that could be considered attributable to 
MTX were identified. Of the 31 toxicities reported while on MTX, six of the toxicities 
reported at follow-up were considered to be attributable to the drug. TYMS 1494del6 was 
the only polymorphism of those examined in this study that had an association with 
toxicities. It was not associated with the overall toxicities reported at follow-up, but did 
show a statistically significant association with the toxicities attributable to MTX. Due to 
the low numbers of toxicities in this study population, specifically the attributable 
toxicities, it is possible that some of the polymorphisms might show an association with 
toxicity if there were more subjects and greater statistical power. 
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Perhaps the most interesting finding of this study is that MCP-1 and IL-8 concentrations 
are positively correlated at baseline and at follow up, and the change in these variables is 
positively and significantly correlated as well. This indicates that these two potent 
biological molecules are at least partly coordinately regulated in patients being treated 
with MTX. 
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Chapter 4 
Pemetrexed Alters Folate Phenotype and Inflammatory Profile in 
EA.hy 926 Endothelial Cells Grown Under Low-Folate Conditions 
 
4.1 Abstract 
Elevated tHcy is a risk factor for several major human pathologies. Emerging evidence 
suggests that perturbations of folate/Hcy metabolism can directly modify production of 
inflammatory mediators. A cell culture model using the EA.hy 926 endothelial cell line 
has been used to investigate the mechanisms whereby chronic “low-folate stress” 
increased synthesis of MCP-1. EA.hy 926 endothelial cells grown in low folate culture 
medium expressed MCP-1 mRNA and protein at higher concentrations than cells grown 
in high folate medium. PMX, an antifolate drug used in the treatment of lung cancer, acts 
by inhibiting TYMS, DHFR, and GARFT. EA.hy 926 endothelial cells grown under Lo 
and Hi folate conditions were treated with PMX. The concentrations of several 
intracellular folate derivatives were measured using stable isotope dilution LC-
MRM/MS. Lo cells had lower folate concentrations and a different distribution of the 
intracellular folate derivatives than Hi cells. Treatment with PMX caused a decrease in 
individual folate analytes and an increase in FA in both Lo and Hi cells. Microarray 
analysis was used to examine changes in gene expression due to PMX treatment. Several 
genes were significantly up or down-regulated in PMX-treated Lo cells. Changes in 
transcript levels of selected targets, including C3, IL-8, and DHFR, were confirmed by 
quantitative RT-PCR. C3 and IL-8 transcript levels were increased in PMX-treated Lo 
cells relative to Lo controls; DHFR transcript levels were decreased. Changes in protein 
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levels of MCP-1, IL-8 and C3 were examined using ELISA. There was no change in the 
concentration of MCP-1 protein in Lo or Hi cells. In Lo cells, IL-8 and C3 protein 
concentrations were increased following PMX treatment. PMX drug treatment was 
shown in this study to have effects that lead to an increase in proinflammatory mediators 
in Lo cells.  
 
4.2 Introduction 
Elevated tHcy, which is usually associated with low folate levels, is a risk factor for 
several major human pathologies, including CVD, stroke (Refsum et al. 1998)(Refsum et 
al. 1998), NTDs in offspring (van der Put et al. 2001), and certain cancers (Ueland et al. 
2001). These conditions originate, at least in part, in the disruption of functions 
underpinned by folate; such disruption can be caused by low intake of B vitamins, 
including folate itself, and/or by mildly dysfunctional genetic polymorphisms of key 
enzymes in the folate metabolic pathway. 
 
The folate metabolic pathway is made up of two sub-pathways (Figure 4.1): one 
facilitates the methylation of substrates such as DNA and proteins and the other supports 
the generation of thymidylate and purines.  
 
PMX was approved for the treatment of malignant pleural mesothelioma in combination 
with Cisplatin in 2004, and was later approved in combination with Cisplatin as a first 
line treatment against locally advanced and metastatic non-squamous non-small cell lung 
carcinoma. Significant benefit is seen only in patients with non-squamous cell lung 
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cancer (Scagliotti et al. 2008), perhaps because histologically, squamous tumors have 
increased TYMS expression (Selvaggi, Scagliotti 2009).  
 
The modification of folate/Hcy metabolism resulting from PMX treatment has 
catastrophic effects on cellular function; while this is beneficial in the context of cancer 
treatment, the resulting damage to normal tissues can lead to unwanted toxicities. Such 
adverse events are limited by administration of FA and vitamin B12 supplementation prior 
to patients receiving PMX therapy (Vogelzang et al. 2003).  
 
Inflammation is a feature of several of the pathologies that are associated with folate/Hcy 
dysregulation, although the relationship between folate/Hcy metabolism and the 
initiation/maintenance of inflammatory processes has not been fully defined. Emerging 
evidence suggests that perturbations of folate/Hcy metabolism can directly modify 
production of inflammatory mediators. A cell culture model using the EA.hy 926 
endothelial cell line has been used to investigate the mechanisms whereby chronic “low-
folate stress” increased synthesis of MCP-1, a chemokine that recruits monocytes into the 
subendothelial cell layer of blood vessels. EA.hy 926 cells grown in low folate culture 
medium expressed MCP-1 mRNA and protein at higher concentrations than cells grown 
in high folate medium (Brown et al. 2006), probably through the action of p38 stress 
kinases (Lu et al. 2009). Treatment with Hcy has been shown to increase secretion of 
MCP-1 and interleukin 8 (IL-8), a neutrophil chemoattractant, in human aortic 
endothelial cells (Poddar et al. 2001) and human monocytes (Zeng et al. 2003)(Zeng et al. 
2003). These in vitro conclusions are supported by a study of young, healthy adults in 
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whom serum MCP-1 levels were positively associated with circulating tHcy 
concentrations and inversely associated with serum and red blood cell folate 
concentrations (Hammons et al. 2009).  
 
Results from ongoing studies in our laboratory indicate that MTX increases synthesis of a 
range of inflammatory mediators, including IL-8 and C3, in EA.hy 926 endothelial cells 
in the context of low folate conditions (unpublished). The aim of the current study was to 
explore the impact of PMX treatment of EA.hy 926 cells on folate phenotype and 
inflammatory protein expression in the context of low and high folate growth conditions. 
 
4.3 Materials and Methods 
4.3.1 Cell Culture 
EA.hy 926 endothelial cells (Edgell, McDonald & Graham 1983) were adapted to growth 
under low folate conditions in Medium 199 (Gibco, Invitrogen, Carlsbad, CA), which 
contains only 10 ng/L (23nM) of FA, supplemented with 10% FCS, non-essential amino 
acids, gentamycin, penicillin G, and fungizone to generate “Lo” cells. Parallel cultures of 
EA.hy 926 cells were grown under standard folate concentrations for that cell line, in 
Medium 199 containing with 4 mg/L (9 μM) FA and supplemented as above to generate 
“Hi” cells (Brown et al. 2006). The PMX-treatment experiments reported here were 
performed in parallel with experiments under similar conditions using MTX, with shared 
control data. 
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4.3.2 Cell Viability Assays 
Lo and Hi cells, grown to confluence in 6-well plates, were maintained for 24 hours in 
fresh medium prior to the addition of 0, 0.05, 0.1, 0.25, 0.5, 1.0, 2, 5, and 10 μM PMX 
(Alimta, gift from Eli Lilly and Co, Indianapolis, Indiana) in duplicate cultures. After a 
further 48 hours, the numbers of live cells remaining were determined with an electronic 
cell counter (Scepter, Millipore, Bedford, MA). 
 
4.3.3 Alamar Blue Assays 
Fresh medium was added to confluent Lo and Hi cell cultures grown in 96-well plates, 
and treated 24 hours later with  0, 0.05, 0.1, 0.25, 0.5, 1.0, 2, 5, and 10 μM PMX. After 
48 hours, metabolic activity was measured by Alamar Blue Assay according to the 
manufacturer’s directions (Trek Diagnostic Systems, West Lake, OH). 
 
4.3.4 Biochemical Phenotyping 
Confluent Lo and Hi cells were maintained for 24 hours in fresh medium prior to 
treatment with 0.5 μM PMX for 48 hours. Intracellular folate derivatives, i.e. 5-MTHF, 
THF, 5,10-MTHF, and unmetabolized FA, were measured by stable isotope dilution 
liquid chromatography, multiple reaction monitoring, mass spectrometry (LC-MRM/MS) 
by Jasbir S Arora and Suhong Zhang as described previously (Huang et al. 2008). 
 
4.3.5 Affymetrix Microarrays 
RNA isolated from triplicate cultures of cells using RNeasy kits (Qiagen Inc., Valencia, 
CA), was reverse transcribed using the Affymetrix WT Expression kit (Ambion, Austin, 
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TX) by Jeanine Jochems. An Agilent Bioanalyzer and RNA6000 Nano LabChips 
(Agilent, Palo Alto, CA) were used to assess the purity and size distribution of the 
products, and quantitation was performed using a Nanodrop spectrophotometer (Thermo 
Scientific, Wilmington, DE) at the Penn Microarray Core. The resulting cDNAs were 
hybridized to Affymetrix Human Gene 1.0 ST microarrays. Robust multi-array analysis 
(RMA) filtered results were imported into Partek Genomics Suite version 6.5 (Partek 
Inc., St Louis, MO) for analysis. A fold change of >2 and false discovery rate of 5%, 
corresponding to a p-value of <0.05, were chosen as the cutoffs. 
 
4.3.6 Quantitative Real Time PCR (qRT-PCR) 
RNeasy kits (Qiagen Inc.) were used to prepare RNA from Lo and Hi cells. Reverse 
transcription was carried out with MMLV reverse transcriptase (Promega, Madison, WI) 
as described previously (Brown et al. 2006). qRT-PCR was carried out in 20 μl reactions 
containing 1 μl cDNA, 1μl Taqman Gene Expression Assay (Applied Biosystems, Foster 
City, CA) in Taqman Universal master mix (Applied Biosystems). The Applied 
Biosystems assay ID numbers were Hs01100879_m1 for C3, Hs00174103_m1 for IL-8 
(CXCL8), and Hs00758822_s1 for DHFR. GAPDH and MCP-1 (CCL2) qRT-PCR 
assays were previously described (Brown et al. 2006). 
 
4.3.7 ELISA 
Confluent Lo and Hi cells were maintained for 24 hours in fresh medium prior to 48 
hours of treatment with 0.5 μM PMX, and media were collected. Concentrations of 
inflammatory mediators of interest were measured in biological triplicates using MCP-1 
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(PeproTech, Inc, Rocky Hill, NJ),  IL-8 (BD Biosciences, San Diego, CA) and C3 
(Innovative Research, Novi, MI) ELISA kits, with adjustment for protein content of the 
cell fraction corresponding to each sample. Each sample was assayed in duplicate. 
 
4.3.8 Statistical Methods 
The two-tailed Student’s t-test method was used to compare differences between means 
using SAS version 9.2 (SAS Institute, Cary, NC). Results with a p value <0.05 were 
considered statistically significant. 
 
4.4 Results 
4.4.1 Determination of PMX Concentration 
In order to find a concentration of PMX that was clinically relevant without causing 
excessive cell death or greatly decreasing metabolic activity, we tested a range of 
concentrations guided by a report that suggested a clinically achievable range of PMX 
concentrations from 0–10 μM (O'Kane et al. 2010). We selected a range of 
concentrations (0, 0.05, 0.1, 0.25, 0.5, 1.0, 2, 5, and 10 μM) to explore using live cell 
counting and Alamar Blue experiments.  
 
4.4.2 The Effect of PMX on EA.hy 926 Endothelial Cell Survival 
Direct counting of live cells using an electronic cell counter indicated that survival of 
PMX-treated Lo cells decreased relative to Lo control cells following treatment with 
increasing concentrations of PMX. At concentrations of PMX ranging from 0.05 to 0.5 
μM, survival of PMX-treated Lo cells was above 60% that of Lo control cells. Survival 
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of Hi cells was not significantly affected by any concentration of PMX up to 10 μM 
relative to untreated Hi cells (Figure 4.2). 
 
 
 
Figure 4-1 Cell survival as a percentage of control determined by electronic cell 
counter. Lo and Hi cells were exposed to 0-10 μM PMX for 48 hours. 
Results represent the mean of biological duplicates. A, Hi cells. B, Lo 
cells. 
 
4.4.3 The Effect of PMX on EA.hy 926 Endothelial Cell Metabolic Activity 
Confluent Lo and Hi cell cultures were maintained for 24 hours in fresh medium and then 
treated with 0.5 μM PMX for 48 hours. Alamar Blue assays were performed with all test 
concentrations of PMX. Lo cells treated with concentrations of PMX from 0.05 to 5 μM 
retained Alamar Blue readouts above 90% of Lo controls. In Hi cells, results indicated 
that treatment with PMX at any concentration did not affect cell metabolic activity (data 
not shown). 
A 
B 
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Based on the results from live cell counting and the Alamar Blue assays, a concentration 
of 0.5 μM PMX was selected for this study, as it is the highest concentration at which 
metabolic activity is retained and live cell numbers of PMX-treated Lo cells are above 
60% of control cells. 
 
4.4.4 Modulation of Folate Phenotype in EA.hy 926 Endothelial Cells by Nutrient 
Deprivation and PMX 
Total folate was significantly lower in Lo control cells than in Hi control cells (98.1 and 
2011.1 ng per mg protein, respectively, p=0.002) (Figure 4.3). This low folate stress is 
accompanied by a difference in the distribution of key folate derivatives. 5-MTHF was 
the most abundant form of folate found in Hi cells, constituting almost 43% of the total, 
and THF was the least abundant, at approximately 23% of the total. In Lo cells, the 
proportion of 5-MTHF is dramatically lower, making up just over 17% of the total 
amount of folate; the percentage of THF is also lower, at 8.6%, the net result being that 
5,10-MTHF was the most abundant folate derivative at 74.3% of the total. 
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Figure 4-2 LC-MRM/MS measurement of folate derivatives. Lo and Hi cells were 
exposed to 0.5μM PMX for 48 hours. Results represent the mean±SD of 
biological triplicates. A, Hi cells. B, Lo cells. *P values <0.05 compared 
with control. NB the scale for Hi cells is an order of magnitude greater 
than the scale for Lo cells. 
 
 
PMX treatment caused a quantitatively large decrease in the concentration of total folate 
in Lo cells, from 98.1 to 56.9 ng per mg protein. This is reflected by a decrease in each 
measured analyte, ie. 5-MTHF (16.8 to 4.3 ng per mg protein), THF (8.4 to 0.58 ng per 
mg protein), and 5,10-MTHF (72.9 to 51.9 ng per mg protein). These quantitatively large 
changes did not reach statistical significance for any of the variables in Lo cells.  In Hi 
cells, PMX treatment caused a statistically significant but proportionally more modest 
decrease in total folate (from 2099.1 to 1506.3 ng per mg protein, p=0.02). This was 
reflected in the individual analytes THF (506.3 to 340.7 ng per mg protein, p=0.04), 5,10-
MTHF (690.9 to 489.8 ng per mg protein, p=0.05), and 5-MTHF (901.8 to 675.8 ng per 
mg protein, p=0.08).  
 
Both Lo and Hi cells treated with PMX demonstrated an increase in unmetabolized FA, 
increasing from 12.4 to 17.8 ng per mg protein in Lo cells (p=0.17) and from 32.9 to 43.3 
ng per mg protein in Hi cells (p=0.0007). These observations suggest that the cells were 
A B 
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able to take up FA in the presence of PMX but that the drug was effective at inhibiting 
DHFR-mediated conversion of FA to DHF and THF, thereby limiting the amount of FA 
that enters into the pool of natural folates.  
 
4.4.5 PMX-Attributable Changes in Gene Expression 
In Lo control cells, C3 mRNA was 15-fold higher and IL-8 mRNA was more than 6-fold 
higher than in Hi control cells (p=0.03 and 0.01, respectively).  MCP-1 mRNA 
concentration was not significantly different between Lo control and Hi control samples. 
 
Affymetrix Human Gene 1.0 ST microarrays were used to assess changes in gene 
expression due to PMX treatment in Lo and Hi cells. A number of gene transcripts were 
significantly up- or down-regulated after PMX treatment in Lo cells (Tables 4.1 and 4.2), 
including several down-regulated transcripts relevant to the cell cycle, though this was 
not seen to be the case in Hi cells.  
 
Genes of particular interest include C3, IL-8 and genes important in folate metabolism. In 
the current study, C3 transcripts were significantly up-regulated in PMX-treated Lo cells 
relative to Lo control cells by 3.6-fold (p=0.0008, step-up p=0.02); C3 was ranked within 
the top fifteen up-regulated genes. IL-8 transcripts were up-regulated in PMX-treated Lo 
cells by 2.2-fold (p=0.04, step-up p=0.2). DHFR transcripts were down-regulated in 
PMX treated Lo cells relative to control by 2.3-fold (p= 0.0001, step-up p=0.002). An 
ongoing body of work in our laboratory suggests that several genes are differentially 
regulated after treatment with different antifolate drugs. These studies suggest that 
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inflammatory proteins, particularly C3 and IL-8, increase in EA.hy cells with antifolate 
drug treatment (unpublished).  
 
The increased levels of IL-8 and C3 transcripts in PMX-treated Lo cells relative to Lo 
control cells were confirmed by qRT-PCR (Figure 4.4). In Lo PMX-treated cells, C3 
mRNA levels were up-regulated 4.3-fold relative to Lo controls (p=0.0008). IL-8 mRNA 
levels were up-regulated 2.1-fold in PMX-treated Lo cells relative to Lo control cells 
(p=0.003).  MCP-1 mRNA was lower in PMX-treated Lo cells (p=0.003). DHFR mRNA 
was down-regulated by almost 3-fold in PMX-treated Lo cells (p=0.001). In Hi cells, 
PMX drug treatment had no measurable effect on C3, IL-8, MCP-1 or DHFR mRNA 
levels. 
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Figure 4-3 Assessment of DHFR, C3, MCP-1 and IL-8 transcripts in Lo and Hi 
cells treated with PMX by qRT-PCR. Lo and Hi cells were exposed to 
0.5μM PMX for 48 hours. Expression of GAPDH was used for 
normalization. Results represent the mean±SD of biological triplicates. A, 
DHFR. B, C3. C, MCP-1. D, IL-8. *P values <0.05 compared with 
respective control. #P values <0.05 for Hi control compared to Lo control. 
 
  
A B 
C D 
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4.4.6 PMX Attributable Changes in C3, IL-8 and MCP-1 Protein Concentrations 
MCP-1 levels were significantly higher in Lo control cells (19.7 ng per mg protein) than 
Hi control cells (11.4 ng per mg protein, p=0.03), which is consistent with previous 
published findings (Figure 4.5). IL-8 protein concentration was significantly higher in Lo 
control cells (28.4 ng per mg protein) than in Hi controls cells (3.9 ng per mg protein, 
p=0.0009). In both control and PMX-treated Hi cells, C3 was not detectable. 
 
MCP-1 concentration in PMX-treated Lo cells (20.4 ng per mg protein) was not 
significantly different from that of Lo control cells. Treatment with PMX increased the 
concentration of IL-8 from 28.4 ng per mg protein in control to 42.9 ng per mg protein 
(p=0.01). In Lo control cells, the C3 level was 18.5 ng per mg protein and in PMX-
treated Lo cells it increased to 25.9 ng per mg protein (p=0.04).  
 
PMX-treated Hi cells had an IL-8 concentration of 3.4 ng per mg protein, similar to the 
concentration in untreated cells. Likewise, the concentration of MCP-1 in PMX-treated 
Hi cells (10.2 ng per mg protein) was not significantly different from that of Hi controls, 
suggesting that treatment with PMX cannot readily modify IL-8 and MCP-1 protein 
levels in folate-replete Hi cells.  
  
 67 
 
 
 
 
Figure 4-4 Assessment of C3, MCP-1 and IL-8 protein in media of Lo and Hi 
cells treated with PMX by ELISA. Lo and Hi cells were exposed to 
0.5μM PMX for 48 hours. Secreted proteins were measured in media. 
Results represent the mean±SD of biological triplicates. A, C3. B, IL-8. C, 
MCP-1. *P values <0.05 compared with respective control. #P values 
<0.05 for Hi control compared to Lo control.  
 
4.5 Discussion 
Emerging evidence suggests that perturbations of folate/Hcy metabolism can directly 
modify production of inflammatory mediators. EA.hy 926 endothelial cells grown in low 
C 
A 
B 
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folate culture medium expressed MCP-1 mRNA and protein at higher concentrations than 
cells grown in medium with high folate levels (Brown et al. 2006). Results from ongoing 
studies in our laboratory indicate that MTX increases synthesis of a range of 
inflammatory mediators, including IL-8 and C3, in EA.hy 926 cells (unpublished). This 
study was designed to examine the effects of PMX treatment of EA.hy 926 cells on folate 
phenotype and inflammatory protein expression in the context of low and high folate 
growth conditions. 
 
EA.hy 926 cells grown under Lo conditions had significantly lower levels of total folate 
than cells grown under Hi conditions and a different distribution of the individual folate 
analytes. In Hi cells, 5-MTHF was the primary form of folate and THF was the least 
abundant, while in Lo cells, 5-MTHF was the least abundant folate derivative and 5,10-
MTHF was the most abundant.  
 
Dysregulation of folate/Hcy phenotype caused by treatment with antifolate drugs could 
compromise cellular functions and elicit pathogenic phenotypes. PMX, an antifolate drug 
used in the treatment of lung cancer, inhibits TYMS, DHFR and GARFT. Treatment with 
0.5 μM PMX caused a reduction in total folate concentrations in both Lo and Hi cells, 
which is reflected in the individual analytes. In PMX-treated Lo cells, there were trends 
toward a decrease in the mean concentrations of all three folate analytes, although this 
did not reach statistical significance. PMX treatment caused a statistically significant 
decrease in total folate in Hi cells, with decreases in all of the folate analytes. FA levels 
were significantly higher in both Lo and Hi cells treated with PMX than in their relative 
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controls, indicating that FA was taken up by the cells but remained unmetabolized due to 
inhibition of DHFR. This is most likely attributable to direct inhibition of the enzyme, 
though we have no data to confirm this. In the case of Lo cells, there may be an 
additional contribution via a decrease in DHFR transcript levels identified by Affymetrix 
microarrays and qRT-PCR. 
 
The effect of PMX on EA.hy 926 cells was examined using an Affymetrix microarray 
platform. Ongoing studies in our laboratory have indicated that MTX increases synthesis 
of IL-8 and C3 (unpublished), suggesting that antifolate drug therapy mobilizes a subset 
of inflammatory mediators. Both IL-8 and C3 transcripts were up-regulated in PMX-
treated Lo cells according to the gene expression data, and warranted further 
investigation. qRT-PCR confirmed that IL-8 and C3 mRNA were up-regulated and 
ELISA assays showed that IL-8 and C3 protein secretion were increased in PMX-treated 
Lo cells. In Hi cells, there was no such increase in the expression or secretion of IL-8 or 
C3 following PMX treatment. Lo cells had higher levels of both of these proteins 
compared to Hi control cells.  
 
The implication of these data is that cells under folate stress have different inflammatory 
potential. The altered potential is more pronounced when cells are further stressed with 
antifolate drug treatment. Antifolate drug treatment, which may be expected to have anti-
inflammatory properties, was shown in this study to have effects that lead to increases in 
pro-inflammatory mediators. This may enhance the anti-tumor effects of the drug or 
contribute to toxicities or comorbidities. Results with folate-replete cells suggest that 
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depression in total folate caused by antifolate drugs does not bring about a change in the 
relative proportions of folate analytes. This, in turn, suggests that the folate metabolic 
pathway is left intact, with a consequence of no modification of inflammatory potential. 
Folate-replete cells are resistant to off target consequences of drug therapy, which might 
describe why patients who receive folate and vitamin B12 prior to treatment with PMX 
have fewer off-target (i.e. toxic) consequences of PMX therapy (Vogelzang et al. 2003).  
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Chapter 5 
Folate Genotype and Phenotype in Lung Cancer: 
 A Case-Control Study 
 
5.1 Abstract 
Lung cancer accounts for more than one quarter of cancer deaths in the United States. 
Although there are clear environmental factors that contribute to lung cancer, such as 
smoking, the fact that all smokers do not get lung cancer suggests that there are gene-
environment interactions at play. Several recent studies have suggested that there is a 
relationship between folate status and lung cancer, although the nature of this relationship 
is complex and not fully understood. Additionally, many genes involved in folate 
metabolism have been implicated in lung cancer. This study was designed to explore this 
relationship in the context of MTHFR 677C>T genotype and folate phenotype. Two 
hundred individuals with non-small cell lung carcinoma (NSCLC) were matched with 
controls based on sex and smoking status. Plasma 5-MTHF and FA and several red blood 
cell (RBC) folate derivatives were measured using LC-MRM/MS. TaqMan assays were 
used to obtain MTHFR 677C>T genotype. In this study population, there was a higher 
prevalence of the MTHFR 677TT genotype in cases than in controls. Cases had 
significantly higher concentrations of total RBC folate and RBC 5-MTHF. The results 
were further analyzed on the basis of sex, smoking status, and the detectability of FA.  
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5.2 Introduction 
The American Cancer Society Cancer Facts and Figures 2011 (American Cancer Society 
2011) estimated that 221,130 new cases of cancer of the lung and bronchus will be 
diagnosed in 2011. Lung cancer is expected to cause 156,940 deaths in the same year, 
accounting for more than one quarter of all cancer deaths. The five year survival rate for 
lung cancer that is discovered early, when the disease is still localized, is 53%. 
Unfortunately, according to the American Cancer Society, only 15% of cancers are 
diagnosed at this point, and for all stages combined the five year survival rate is only 
16%. For NSCLC specifically, the five year survival rate is 17%.  
 
While 80-90% of lung cancer cases occur in smokers, only 10-15% of smokers ever get 
lung cancer (Schwartz 2004), suggesting that important gene-environment interactions 
underpin lung cancer susceptibility. 
  
A low-folate/high Hcy phenotype is associated with a wide range of pathologies, 
including lung cancer (Shen et al. 2003, Voorrips et al. 2000). This phenotype can result 
from genetic factors or nutritional deficiencies/insufficiencies. Several vitamins are 
important in the folate metabolic pathway, including folate, vitamin B12, and riboflavin. 
There are also several genetic polymorphisms in pathway enzymes that can affect the 
distribution of folate derivatives within the pathway. Dysregulation of folate/Hcy 
phenotype due to genotype or caused by treatment with antifolate drugs could 
compromise cellular functions and elicit pathogenic phenotypes. 
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There are two mechanisms by which folate deficiency may affect cancer risk. The first is 
that impaired dTMP synthesis increases rates of uracil misincorporation into DNA; the 
second is depressed SAM synthesis leading to decreased methylation, which is a nearly 
universal finding in tumorigenesis (Choi, Mason 2000).  
 
The folate metabolic pathway is made up of two sub-pathways, one responsible for DNA 
synthesis and the other for methylation of DNA and proteins. The most important, and 
consequently most widely studied, SNP in the folate metabolic pathway is the MTHFR 
677C>T polymorphism. The MTHFR 677TT genotype has been associated with higher 
levels of tHcy when folate levels are low (Kluijtmans et al. 2003, Jacques et al. 1996, 
Harmon et al. 1996). Consensus in the literature suggests that TT homozygotes who are 
folate replete have similar tHcy levels to their CC and CT peers.  
 
Several studies have shown an inverse relationship between dietary folate intake and lung 
cancer. A protective impact of folate on lung cancer risk has been shown in both a case-
control study of a racially heterogeneous Texas population of former smokers (Shen et al. 
2003), and a prospective cohort study of Dutch males (Voorrips et al. 2000). A more 
recent study using data from two trials examined the effects of FA and vitamin B12 on 
lung cancer incidence (Ebbing et al. 2009). The subjects examined in this study were 
treated with FA plus vitamin B12 for a median of 39 months with an additional 38 months 
of post-trial follow up. Ten percent of the subjects who received the treatment were 
diagnosed with cancer versus 8.4% of subjects who did not receive treatment. Cancer 
deaths were higher in the treated group (4.0%) than in the group that did not receive 
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treatment (2.9%). In contrast to the above studies which suggest that folate is protective 
against lung cancer, the study by Ebbing et al. showed an increase in lung cancer 
incidence with FA supplementation, suggesting that folate enhances tumor initiation or 
enhances progression to clinical presentation. 
 
Several groups have also reported that functional polymorphisms of genes associated 
with folate metabolism may confer an increased risk of lung cancer, including MTHFR 
677C>T and 1298A>G (Jeng et al. 2003, Shi et al. 2005b, Boccia et al. 2010, Hung et al. 
2007), MTR 2756A>G and MTRR 66A>G (Shi et al. 2005a) and TYMS 3’UTR ins/del (Shi 
et al. 2005c). In a region of China with an extremely high lung cancer mortality rate, a 
study of lung cancer and polymorphisms in folate metabolizing genes identified 
significant odds ratios for variants of MTHFR, CBS and RFC1 (Shen et al. 2005). 
 
This study was designed to compare the distribution of MTHFR 677C>T genotype in 
individuals with NSCLC and matched controls. Additionally, the relationship between 
MTHFR 677C>T genotype on biochemical parameters was examined. 
 
5.3 Materials and Methods 
5.3.1 Subject subjects 
Lung cancer cases were recruited under the direction of Dr. Anil Vachani from the 
Hospital of the University of Pennsylvania (HUP) and Penn Presbyterian Hospital. Nurse 
coordinators identified eligible subjects among lung cancer patients who had been 
referred to the Thoracic Surgery or Thoracic Oncology clinic for work-up and treatment. 
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Patients with histologically confirmed primary NSCLC who had not received any prior 
treatment were invited to participate in this study. Control subjects were selected from 
patients seen by general medicine physicians and also from patients seen at pulmonary 
clinics for non-malignant lung disease (such as chronic obstructive pulmonary disorder). 
The study was approved by the University of Pennsylvania Institutional Review Board 
and all subjects provided written informed consent.  
 
Demographic and lifestyle information was collected from all subjects, including age, 
self-reported race, current and previous tobacco use, dietary history, height, weight, BMI, 
occupational history, family cancer history, presenting symptoms, medications (including 
vitamins), type and length of exposure to pollutants, and concomitant illnesses. 
Additional information collected from lung cancer cases included TNM stage (TMN 
Classification of Malignant Tumors cancer staging system), differentiation, and cell type.  
Blood samples were collected in EDTA and CPT tubes. Serum and plasma stored 
samples were prepared and stored. Control subjects provided 50 mL of blood after 
consenting. Samples were all stored at -80°C after collection.  
 
The sub-study presented in this report consists of two hundred Caucasian individuals with 
NSCLC with controls matched approximately for sex and smoking status selected from 
the main study. Analysis was based on a subset of the available data (i.e. MTHFR 
677C>T genotype, folate phenotype and smoking status). 
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5.3.2 Genotyping 
DNA was extracted from whole blood using QIAamp DNA Mini Kits (Qiagen, Santa 
Clarita, CA). For genotyping of MTHFR 677C>T, TaqMan genotyping methods were 
used on a DNA Engine Opticon 2 continuous fluorescence detection system or a 
Chromo4 real time detection system (Bio-Rad, Hercules, CA). 
 
PCR amplifications took place in 20 μl volumes containing 20 ng genomic DNA, 
forward and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions 
consisted of an initial incubation at 50°C for 2 minutes, 95°C for 10 minutes, and 50 
cycles of 92°C for 30 seconds and 56°C for 1 minute. Dual fluorescence was measured at 
the end of each cycle. Genotype interpretations were performed with Opticon Monitor 
Analysis software, version 2.02 and version 3 (Bio-Rad). 
 
5.3.3 Biochemical Phenotyping 
Select folate derivatives (5-MTHF, THF and 5,10-MTHF) and FA in red blood cells 
(RBCs) and plasma were measured  in collaboration with Dr. Jasbir Arora and Dr. 
Suhong Zhang by stable isotope dilution LC-MRM/MS using methods previously 
described (Huang et al. 2007, Huang et al. 2008). Hemoglobin was measured using the 
Drabkin Hemoglobin Assay. Hematocrit was calculated from the hemoglobin values 
based on the commonly used (standard) three-fold conversion (hematocrit = 3 x 
hemoglobin).  
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5.3.4 Statistical Analysis 
All statistical tests were performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC). 
Comparisons of continuous variables between cases and controls were done using the 
Wilcoxon ranked sum test. Fisher’s exact test was used to compare MTHFR 677C>T 
genotype distribution between cases and controls. 
 
5.4 Results 
5.4.1 Differences in phenotypic variables 
The concentrations of plasma 5-MTHF and several RBC folate derivatives are detailed in 
Table 5-1. Median plasma 5-MTHF in lung cancer cases was 43.05 nmol/L, compared to 
46.58 nmol/L for controls (p=0.09). In concert with plasma levels, RBC total folate was 
significantly higher in lung cancer cases than in controls (1139.14 and 941.12 nmol/L, 
respectively, p=0.005). In addition, RBC 5-MTHF was higher in cases than in controls, at 
1002.11 nmol/L and 874.86 nmol/L, respectively (p=0.02). RBC 5,10-MTHF was 13.96 
nmol/L for cases and 13.38 nmol/L for controls (p=0.34). RBC THF was 28.92 nmol/L 
for cases and 28.09 nmol/L for controls (0.62). The ratio of 5-MTHF:THF was 37.04 in 
cases and 34.18 in controls (p=0.38).  
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Table 5-1 Plasma and RBC variables in cases and controls 
Variable Cases Controls p2 
PLASMA 5-
MTHF (nmol/L) 1 
43.05 [27.60-62.25] (199) 46.58 [34.22-63.99] (199) 0.09 
Total RBC folate 
(nmol/L)1 
1139.14 [783.43-1649.14] (200) 941.12 [736.05-1340.97] (200) 0.005 
RBC 5-MTHF 
(nmol/L) 1 
1002.11 [667.83-1513.08] (200) 874.86 [650.87-1258.78] (200) 0.02 
RBC THF 
(nmol/L) 1 
28.92 [17.79-61.63] (200) 28.09 [19.30-53.44] (200) 0.62 
RBC 5,10-MTHF 
(nmol/L) 1 
13.96 [7.46-29.25] (200) 13.38 [7.32-25.71] (200) 0.34 
Ratio  
5-MTHF:THF1 
37.04 [20.66-54.73] (199) 34.18 [19.34-49.45] (200) 0.38 
1Median [Inter-Quartile Range] (n) 
2p value by Wilcoxon 
 
5.4.2 Genotype Frequencies 
The distribution of MTHFR 677C>T (Table 5-2) was in Hardy Weinberg equilibrium for 
controls in this study, although for cases it bordered on not being in HWE (p=0.05). 
There were 38 cases that had the MTHFR 677TT genotype and only 24 controls had this 
genotype. This striking quantitative difference suggests that there are 50% more MTHFR 
667TT homozygotes, though this difference does not reach statistical significance 
(p=0.15), most likely due to low numbers in this study population. 
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    Table 5-2     Categorical variable distributions in  
    cases and controls 
 Cases  Controls  
Variable n (%) n (%) p* 
MTHFR   0.15 
     CC 78 (39.4) 87 (44.2)  
     CT 82 (41.4) 86 (43.5)  
     TT 38 (19.2) 24 (12.2)  
Smoker-Current    
     Yes 37 (18.5) 37 (18.5)  
     No 163 (81.5) 163 (81.5)  
Smoker-Ever    
     Yes 172 (86) 134 (67)  
     No 28 (14) 66 (33)  
       *p value by Fisher’s exact test 
 
5.4.3 Phenotypic Variables by Smoking Status 
Individuals in this study were matched for sex and smoking status. There were 37 current 
smokers in both the cases and the controls, and 163 current non-smokers (Table 5-2). One 
hundred and seventy two cases and 134 controls were self-reported as previous smokers. 
Non-smoking cases had significantly higher total RBC folate than non-smoking controls 
(p=0.02), but otherwise there were no significant relationships between smoking status 
and the continuous variables examined in this study.  
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Table 5-3 Plasma and RBC folate derivatives in cases and controls by smoking 
status 
Variable Current 
Smoker 
Cases Controls p2 
Plasma 5-MTHF No 43.51 [28.47-62.68] (162) 48.54 [34.22-65.29] (162) 0.11 
(nmol/L)1 Yes 37.09 [19.20-57.46] (37) 44.40 [34.39-50.06] (37) 0.62 
Total RBC folate No 1160.16 [799.59-1705.03] (163) 1011.55 [763.45-1358.14] (163) 0.02 
(nmol/L)1 Yes 1036.79 [640.47-1566.08] (37) 836.64 [682.13-1059.99] (37) 0.18 
RBC 5-MTHF No 1011.69 [696.24-1538.35] (163) 905.96 [659.56-1309.95] (163) 0.05 
(nmol/L)1 Yes 883.07 [601.47-1317.70] (37) 771.58 [553.55-961.41] (37) 0.34 
RBC THF No 29.24 [17.76-62.24] (163) 28.49 [19.36-55.40] (163) 0.84 
(nmol/L)1 Yes 28.21 [17.943-41.18] (37) 23.49 [18.28-43.05] (37) 0.41 
RBC 5,10-MTHF No 13.78 [6.77-28.97] (163) 13.86 [7.38-32.24] (163) 0.77 
(nmol/L)1 Yes 14.13 [8.64-30.00] (37) 10.50 [5.30-18.37] (37) 0.13 
Ratio 5-MTHF:THF No 37.47 [20.66-54.73] (162) 34.44 [18.86-48.81] (163) 0.31 
(nmol/L)1 Yes 33.52 [20.74-54.38] (37) 33.04 [23.27-55.54] (37) 0.91 
1Median [Inter-Quartile Range] (n) 
2p value by Wilcoxon 
 
5.4.4 Phenotypic Variables by MTHFR 677C>T Genotype 
Folate status between cases and controls was analyzed for each MTHFR 677C>T 
genotype individually (Table 5-3). For each genotype, cases had higher levels of total 
RBC folate and 5-MTHF than controls. Although quantitatively striking, breakdown into 
these categories did not yield statistically significant results, probably based on small 
numbers compared to the population as a whole, which did yield a significant result. 
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Table 5-4 Plasma and RBC folate derivatives in cases and controls by MTHFR 
677C>T genotype 
 Cases Controls p2 
MTHFR 677C>T Plasma 5-MTHF (nmol/L)1  
     CC 43.49 [26.25-58.76] (77) 44.84 [34.39-65.29] (87) 0.09 
     CT 43.42 [31.65-66.16] (82) 49.19 [34.74-63.99] (85) 0.39 
     TT 42.31 [28.47-66.16] (38) 48.10 [29.53-63.55] (24) 0.89 
MTHFR 677C>T Total RBC folate (nmol/L) 1  
     CC 1034.02 [680.15-1566.08] (78) 905.96 [716.66-1254.75] (87) 0.23 
     CT 1132.88 [806.21-1643.97] (82) 1000.47 [736.10-1381.82] (86) 0.08 
     TT 1392.44 [933.97-1915.62] (38) 1080.99 [776.74-1621.63] (24) 0.07 
MTHFR 677C>T RBC 5-MTHF (nmol/L) 1  
     CC 986.04 [671.72-1527.00] (78) 869.04 [684.35-1222.91] (87) 0.20 
     CT 1124.44 [754.25-1560.50] (82) 956.79 [687.08-1331.02] (86) 0.06 
     TT 720.80 [518.34-1304.59] (38) 582.70 [378.40-979.60] (24) 0.11 
MTHFR 677C>T RBC THF (nmol/L) 1  
     CC 23.23 [12.03-31.14] (78) 22.79 [14.10-31.80] (87) 0.71 
     CT 28.18 [18.10-46.23] (82) 29.13 [19.23-46.25] (86) 0.75 
     TT 339.11 [117.044-574.05] (38) 310.20 [108.23-464.95]  (24) 0.69 
MTHFR 677C>T RBC 5,10-MTHF (nmol/L) 1  
     CC 9.78 [5.19-15.34] (78) 9.21 [5.17-17.44] (87) 0.96 
     CT 13.37 [7.40-26.66] (82) 13.90 [7.69-21.16] (86) 0.92 
     TT 157.41 [38.35-232.36] (38) 94.66 [37.50-189.74] (24) 0.31 
MTHFR 677C>T Ratio 5-MTHF:THF1  
     CC 46.84 [33.52-65.75] (77) 38.71 [29.05-59.20] (87) 0.11 
     CT 39.29 [24.88-53.81] (82) 35.24 [22.39-44.49] (86) 0.11 
     TT 1.87 [1.05-10.47] (38) 2.51 [1.08-5.01] (24) 0.84 
1Median [Inter-Quartile Range] (n) 
2p value by Wilcoxon 
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5.4.5 Phenotypic Variables by Sex 
The cases and controls in this study were compared based on sex (Table 5-5). Plasma 5-
MTHF was higher in male controls at 46.58 nmol/L than in male cases at 37.35 nmol/L 
(p=0.009). Among males, case-control status did not have a statistically significant effect 
on any of the RBC folate derivatives. Among females, total RBC folate was 1215.51 
nmol/L in cases and 905.72 nmol/L in controls, a statistically significant difference 
(p=0.002). RBC 5-MTHF was also lower in controls than in cases, at 1036.34 and 865.13 
nmol/L (p=0.007).  
 
Table 5-5 Phenotypic variables in cases and controls by sex 
Variable Sex Cases Controls p2 
PLASMA 5- M 37.35 [22.98-54.41] (103) 46.58 [34.39-62.25] (98) 0.009 
MTHF (nmol/L)1 F 47.66 [31.52-71.39] (96) 46.14 [34.22-66.16] (101) 0.80 
Total RBC folate M 1117.93 [763.84-1752.86] (103) 1012.82 [772.03-1370.22] (99) 0.37 
(nmol/L)1 F 1215.51 [799.59-1629.18] (97) 905.72 [701.95-1322.61] (101) 0.002 
RBC 5-MTHF  M 965.45 [624.11-1544.42] (103) 895.17 [694.05-1320.46] (99) 0.67 
(nmol/L)1 F 1036.34 [703.88-1500.97] (97) 865.13 [610.44-1248.36] (101) 0.007 
RBC THF  M 28.48 [16.88-62.24] (103) 26.44 [19.37-52.43] (99) 0.88 
(nmol/L)1 F 30.52 [18.15-59.58] (97) 28.57 [18.50-53.63] (101) 0.60 
RBC 5,10-MTHF M 13.78 [7.73-28.83] (103) 13.75 [7.11-24.34] (99) 0.28 
(nmol/L)1 F 14.13 [7.29-30.90] (97) 13.33 [7.48-28.23] (101) 0.78 
Ratio  M 35.64 [19.31-54.73] (103) 34.44 [20.31-54.38] (99) 0.87 
5-MTHF:THF1 F 38.17 [21.46-54.92] (96) 33.92 [17.65-46.10] (101) 0.26 
1Median [Inter-Quartile Range] (n) 
2p value by Wilcoxon 
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5.4.6 Biochemical variables by FA Detectibility 
There were a total of 139 individuals in this study with non-detectable levels of plasma 
FA (Table 5-6). Of these 139 individuals, 81 are cases and 58 are controls. Thus, 118 
cases and 141 controls have detectable levels of plasma FA. Subjects were separated 
based on FA detectability and cases and controls were compared within those groups. 
Plasma 5-MTHF, total RBC folate and RBC THF were all significantly higher in cases 
than in controls (p=0.04, 0.002 and 0.01, respectively). 
 
Table 5-6 Phenotypic variables in cases and controls by FA detectibility 
Variable FA Cases Controls p2 
Plasma 5-MTHF  No 44.84 [28.47-59.64] (81) 42.59 [28.86-56.15] (58) 0.79 
(nmol/L)1 Yes 41.81 [27.21-63.12] (118) 50.06 [37.44-66.16] (141) 0.04 
Total RBC folate No 991.95 [736.83-1623.96] (81) 889.48 [704.98-1355.57] (58) 0.28 
(nmol/L)1 Yes 1182.60 [868.22-1705.03] (118) 978.94 [761.36-1331.60] (141) 0.002 
RBC 5-MTHF  No 856.51 [606.19-1500.97] (81) 823.64 [648.54-1285.01] (58) 0.43 
(nmol/L)1 Yes 1084.96 [735.95-1527.00] (118) 900.50 [652.53-1251.31] (141) 0.01 
RBC THF  No 29.24 [17.94-60.30] (81) 27.49 [22.65-44.39] (58) 0.80 
(nmol/L)1 Yes 28.01 [17.76-61.75] (118) 28.140 [18.28-58.67] (141) 0.68 
RBC 5,10-MTHF No 16.03 [8.22-35.06] (81) 13.33 [6.95-23.51] (58) 0.29 
(nmol/L)1 Yes 13.08 [7.33-28.31] (118) 13.44 [7.53-26.12] (141) 0.75 
Ratio  No 35.84 [20.66-51.96] (81) 33.80 [22.70-41.80] (58) 0.68 
5MTHF:THF Yes 37.83 [20.74-54.95] (118) 33.92 [18.85-51.92] (141) 0.36 
1Median [Inter-Quartile Range] (n) 
2p value by Wilcoxon 
 
5.5 Discussion 
Results from this study indicate that in this population, lung cancer cases had higher total 
RBC folate and 5-MTHF concentrations. Although there is precedence in the study by 
Ebbing et al. for an association with lung cancer and enhanced folate status, the 
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mechanism by which this might occur is not clear. One possibility is that there is a 
difference between lung cancer cases and controls that leads to enhanced folate status. 
For example, it is plausible that if an individual has a more efficient folate uptake system, 
and/or increased ability to take up and convert FA, and/or superior polyglutamation it 
would lead to increased intercellular folate accumulation. If a significant proportion of 
lung cancer cases have an enhanced capacity to acquire intracellular folate and retain it 
(perhaps increasing the likelihood of cells which are faced with other oncogenic stimuli -
for example smoking- to become cancerous), that might go a long way to explaining why 
some people get lung cancer and others don’t. One way to study this issue is to look at 
polymorphisms in folate transporters, other genes in the folate metabolic pathway, and 
genes involves in polyglutamation. In particular, it would be interesting to examine 
polymorphisms in RFC-1, DHFR, and folylpolyglutamate synthase (FPGS). 
 
The difference in MTHFR 677C>T genotype frequencies between cases and controls in 
this study is striking, and supports a relationship between MTHFR 677C>T 
polymorphisms and lung cancer. In this study, the results do not reach statistical 
significance, likely due to low numbers. This warrants further investigation using a larger 
study population.  
 
For each genotype, cases had higher levels of total RBC folate and 5-MTHF than 
controls. This is an indication that elevated total RBC folate and RBC 5-MTHF in this 
study population is not genotype-specific. Although quantitatively striking, low numbers 
compared to the population as a whole may have led to a loss of statistical power. To 
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establish whether or not each case genotype class does have significantly higher levels of 
these variables than their matched controls, the full population from which this subset 
was taken should be used for further analysis. An Infinium platform has been used to 
analyze all of the samples from this full study, and this data could be used for further 
genotype analysis.  
 
The results from the sex-based analysis suggest that the effect is more prominent in, or 
perhaps even restricted to, females. This could reflect hormonal differences that are 
involved with oncogenic processes in women that are not present in men, although this is 
highly speculative. Given the long latency period for the development of lung cancer and 
the multi-step nature of oncogenic processes, the potential for an estrogenic-input into the 
genesis of lung cancer is possible. 
 
There is precedence for an association between FA and other cancer types. After FA 
fortification was mandated by the FDA in 1998, there was an increase in colorectal 
cancer incidence (Mason et al. 2007). A similar relationship could exist with lung cancer, 
which may not have been detected immediately due to the latency period of this disease.  
 
Surely this study has generated some provocative results and more analysis has to be 
done, preferably on an enhanced dataset. The study population from which this sub-study 
was obtained has hundreds more Caucasian cases and controls that can be phenotyped. A 
study of this group would serve as independent repeat dataset, which could then be 
combined with this study group to analyze the genotype frequencies with greater numbers 
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and thus more statistical power. Additionally, an enhanced dataset could be used to 
examine polymorphisms in other genes that have been associated with lung cancer risk. 
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Chapter 6 
General Conclusions and Future Directions 
 
6.1 Discussion and Conclusions 
The research reported in this thesis has led to several overall conclusions. 
 
1. There are associations of serum folate, RBC folate, and MTHFR 677C>T 
genotype with MCP-1. 
In females, MCP-1 concentrations were positively correlated with tHcy and negatively 
correlated with both serum and red blood cell folate; female smokers and MTHFR 677T 
carriers had particularly elevated MCP-1 concentrations. Similar relationships were not 
seen in males. The implication of the study, which was conducted in a population of 
healthy young adults, is that MCP-1-mediated inflammation may be a contributing factor 
to pathologies in which folate/Hcy dysregulation is an underlying feature. There are 
several diseases for which there is evidence in the literature suggesting involvement of 
folate/Hcy metabolic dysregulation, including RA and lung cancer. This initial research 
raised questions about whether similar results would be seen in subjects with such 
diseases. 
 
2.   MCP-1 and IL-8, both potent inflammatory mediators, track together in a 
study of patients taking methotrexate.  
The methotrexate study explored the effect of antifolate drug treatment on clinical and 
biochemical variables and the relationship between genetic polymorphisms in several 
folate-metabolizing enzymes in patients with arthritic conditions. It examined the 
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relationships among concentrations of MCP-1 and IL-8 and the patients’ clinical status. 
Changes in MCP-1 and IL-8 concentration were positively correlated, which indicates 
that these two potent and potentially pathogenic biological molecules are at least partly 
coordinately regulated in patients being treated with MTX. 
 
3. Treatment with the antifolate drug pemetrexed alters folate phenotype and 
the inflammatory profile in EA.hy 926 endothelial cells. 
The implication of the data from the PMX cell culture study is that cells under folate 
stress have different inflammatory status, as measured by levels of MCP-1, IL-8 and C3. 
The difference between folate-replete and folate stressed cells is more pronounced when 
cells are further challenged with PMX, an antifolate drug. 
 
4.  Folate phenotype and MTHFR 677C>T genotype are associated with lung 
cancer status. 
The lung cancer case-control study aimed to explore the relationship between folate 
phenotype, MTHFR 677C>T genotype and lung cancer. The results suggest that the 
MTHFR TT genotype is more frequent in cases than in controls. Additionally, lung 
cancer cases had higher levels of total RBC folate and RBC 5-MTHF, an observation that 
accords with a recent retrospective report in which the use of FA supplements was 
associated with elevated lung cancer incidence and mortality. 
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6.2 Future Directions 
The EA.hy 926 cell line could be used to determine if the response in PMX-induced 
inflammatory protein production and secretion is dose-dependent. This can further be 
used to establish whether there is a concentration at which FA becomes protective. In 
addition, this cell line could be used to catalog the inflammatory mediators (in addition to 
MCP-1, IL-8 and C3) that are differentially regulated under conditions of (1) folate stress 
and (2) antifolate drug treatment.  
 
Any inflammatory mediators identified in the cell culture studies could also be monitored 
in patients with inflammatory conditions taking antifolate drugs, like MTX, to see if they 
are coordinately regulated. Our archived MTX study sample set could be used for this 
purpose. Larger studies could be designed to fully characterize the spectrum of immune 
modulation with sufficient statistical power.  
 
The data used in this lung cancer study was obtained from a four-year study in which 
approximately 2000 subjects (roughly equal numbers of cases and controls) were 
recruited. The full sample set for the lung cancer study has been genotyped using an 
Infinium platform. This information could be used in conjunction with the subset in this 
study to determine if the increased MTHFR 677TT frequency observed in the subset 
holds in the larger data set to a significant degree. In addition, one could look at other 
folate-related genes associated with lung cancer case status. This expanded sample set 
could be used as a replication set for the folate findings reported here. Going forward, a 
prospective study could be designed to study if PMX outcome variables (tumor response, 
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survival, etc.) are modified by folate phenotype and genotype. In addition, based on the 
changes observed in inflammatory profiles in cell culture and other study subjects, this 
case-control study could be used to explore potential differences in the inflammatory 
profile of lung cancer patients being treated with PMX. In light of the results observed in 
cell culture experiments with PMX, it would be instructive to study human subjects 
before and after receiving PMX to determine whether there are any changes in the 
inflammatory profile (MCP-1, C3, IL-8 and others to be determined as outlined above). 
An important future direction would be to use to use the full sample set to further define 
the differences in males and females that were reported in this thesis. Any confirmation 
of gender differences would mandate consideration of hormonal differences acting in 
concert with folate variables to enhance lung cancer risk in females. Such studies would 
include genes involved in estrogen metabolism. 
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Appendix A 
Tables from Chapter 3: Folate Phenotype, Genotype, Inflammation and Disease Activity 
in Rheumatoid Arthritis Patients Treated with Methotrexate  
 
Tables 1-5 detail the relationship between clinical and biochemical variables and MTHFR 
1298A>C, DHFR c.86+60_78, TYMS 5’ VNTR, TYMS 1494del6, and CCL2 (-2518)A>G 
genotypes. 
 
Tables 6-10 detail the relationship between the genetic polymorphisms of MTHFR 
677C>T, MTHFR 1298A>C, DHFR c.86+60_78, TYMS 5’ VNTR, and TYMS 1494del6 
and toxicities. 
 
Tables from Chapter 4: Pemetrexed Alters Folate Phenotype and Inflammatory Profile in 
EA.hy 926 Endothelial Cells Grown Under Low Folate Conditions 
 
Tables 11-12 contain the results from the Affymetrix analysis of “Lo” and “Hi” cells 
treated with 0.5 μM PMX.
 
 
Table 1 Effects MTHFR 1298A>C genotype on variables at baseline, follow-up and the difference between the time points 
 
  AA AC CC  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
BMI Baseline 31.38 8.43 28.90 46 30.44 6.04 29.05 56 27.43 5.55 28.90 7 0.38 
Follow up 31.17 8.20 29.40 46 30.66 5.95 29.85 56 27.59 5.28 29.50 7 0.45 
Difference -0.21 3.25 0.00 46 0.22 1.63 0.05 56 0.16 0.67 0.50 7 0.67 
p2 0.66    0.32    0.56     
tHcy Baseline 10.33 4.35 9.20 47 11.00 2.74 11.00 59 9.07 2.57 8.85 6 0.34 
Follow up 10.26 2.66 10.20 47 10.56 2.60 10.30 59 10.10 1.99 10.40 6 0.80 
Difference -0.07 3.56 0.30 47 -0.44 2.79 -0.80 59 1.03 1.53 0.70 6 0.50 
p2 0.89    0.23    0.16     
Plasma 5-MTHF Baseline 57.09 34.48 53.50 47 51.57 28.23 42.90 59 65.98 31.04 66.85 6 0.44 
(nmol/L) Follow up 34.39 15.61 33.90 47 45.07 41.26 39.90 59 34.03 22.05 28.55 6 0.22 
Difference -22.70 40.13 -15.20 47 -6.50 49.29 -11.00 59 -31.95 37.39 -18.60 6 0.12 
p2 0.0003    0.32    0.09     
RBC total folate Baseline 1328.84 480.09 1270.75 46 1419.68 648.24 1314.30 57 1515.50 780.59 1041.70 5 0.65 
(nmol/L) Follow up 1129.95 441.84 1052.05 46 1281.45 593.73 1167.80 57 1608.74 696.27 1382.00 5 0.11 
Difference -198.89 470.08 -184.80 46 -138.23 497.24 -123.40 57 93.24 404.44 81.70 5 0.42 
p2 0.006    0.04    0.63     
RBC 5-MTHF Baseline 1158.12 510.24 1114.60 46 1357.89 611.34 1261.10 57 1470.12 749.53 1016.00 5 0.17 
(nmol/L) Follow up 952.31 414.24 883.70 46 1209.19 569.34 1094.50 57 1538.30 662.52 1350.20 5 0.009 
Difference -205.81 452.96 -186.40 46 -148.70 491.79 -140.60 57 68.18 401.88 50.10 5 0.45 
p2 0.004    0.03    0.72     
 
 
 
  AA AC CC  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
RBC THF Baseline 138.61 252.44 33.05 46 51.21 83.71 29.70 57 37.20 21.13 26.60 5 0.04 
(nmol/L) Follow up 139.92 244.30 37.80 46 56.49 68.50 36.10 57 56.78 25.76 48.10 5 0.04 
Difference 1.32 89.76 1.50 46 5.28 37.83 5.30 57 19.58 10.93 16.10 5 0.82 
p2 0.92    0.30    0.02     
RBC 5,10-MTHF Baseline 37.97 63.22 11.51 46 17.39 20.25 11.58 57 14.23 5.69 10.48 5 0.06 
(nmol/L) Follow up 42.75 71.79 12.56 46 20.79 24.18 12.80 57 18.14 10.05 11.58 5 0.08 
Difference 4.78 20.90 0.75 46 3.40 8.94 0.60 57 3.91 4.39 1.10 5 0.90 
p2 0.13    0.006    0.12     
Ratio  Baseline 36.74 23.92 40.73 46 44.58 20.92 43.05 57 41.17 7.13 39.53 5 0.20 
5-MTHF:THF Follow up 28.91 21.93 29.06 46 38.15 44.47 30.87 57 28.54 8.68 28.28 5 0.40 
Difference -7.83 15.76 -5.23 46 -6.43 46.72 -13.00 57 -12.63 3.22 -11.95 5 0.93 
p2 0.002    0.30    0.0009     
Plasma FA Baseline 5.78 17.91 0.00 47 9.56 34.20 0.00 59 0.95 2.33 0.00 6 0.65 
(nmol/L) Follow up 33.38 52.54 10.70 47 39.35 74.65 7.90 59 27.32 16.24 34.05 6 0.84 
Difference 27.60 47.12 3.80 47 29.79 59.33 6.00 59 26.37 15.42 34.05 6 0.97 
p2 0.002    0.003    0.009     
B12 Baseline 487.14 230.50 422.50 44 602.93 265.94 569.00 55 567.50 275.00 512.50 6 0.08 
Follow up 491.80 242.32 390.00 44 636.56 252.39 656.00 55 652.17 293.37 598.00 6 0.02 
Difference 4.66 160.50 2.50 44 33.64 120.03 0.00 55 84.67 82.81 61.00 6 0.32 
p2 0.85    0.04    0.06     
 
 
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype 
 AA AC CC  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
PGA Baseline 41.33 17.91 41.00 45 49.36 21.88 46.00 56 41.71 23.73 34.00 7 0.13 
Follow up 31.11 16.63 33.00 45 25.43 14.81 24.00 56 17.57 8.22 19.00 7 0.04 
Difference -10.22 21.50 -7.00 45 -23.93 25.38 -19.50 56 -24.14 29.82 -17.00 7 0.02 
p2 0.003    <0.0001    0.08     
ARA class Baseline 1.98 0.70 2.00 44 2.11 0.73 2.00 56 2.00 0.58 2.00 7 0.65 
Follow up 1.86 0.59 2.00 44 1.70 0.66 2.00 56 1.57 0.53 2.00 7 0.30 
Difference -0.11 0.58 0.00 44 -0.41 0.76 0.00 56 -0.43 0.79 0.00 7 0.09 
p2 0.20    0.002    0.20     
CRP Baseline 1.47 2.72 0.80 46 1.36 2.03 0.70 57 0.90 0.92 0.70 5 0.87 
Follow up 0.89 0.66 0.70 46 1.29 2.68 0.50 57 1.08 1.52 0.50 5 0.62 
Difference -0.57 2.44 -0.05 46 -0.07 1.58 -0.10 57 0.18 1.85 0.00 5 0.40 
p2 0.12    0.73    0.84     
MCP-1 Baseline 370.39 268.97 294.00 49 368.50 164.61 330.50 62 480.57 240.20 424.00 7 0.43 
Follow up 412.12 281.81 364.00 49 428.82 192.10 404.50 62 463.57 284.80 428.00 7 0.84 
Difference 41.73 252.67 42.00 49 60.32 151.19 61.50 62 -17.00 109.55 21.00 7 0.60 
p2 0.25    0.003    0.70     
IL-8 Baseline 9.90 5.92 7.93 49 11.67 16.73 6.79 62 11.47 5.94 10.33 7 0.77 
(pg/mL) Follow up 11.58 12.06 7.75 49 9.41 6.77 7.25 62 9.73 4.95 8.71 7 0.47 
Difference 1.68 12.18 -0.36 49 -2.26 15.36 -0.27 62 -1.74 4.22 -1.48 7 0.32 
p2 0.34    0.25    0.32     
 
 
Table 2 Effects of  DHFR c.86+60_78 on variables at baseline, follow-up and difference 
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
ARA class Baseline 2.10 0.70 2.00 21 2.03 0.77 2.00 58 2.04 0.58 2.00 28 0.94 
Follow up 1.90 0.44 2.00 21 1.72 0.72 2.00 58 1.71 0.53 2.00 28 0.49 
Difference -0.19 0.51 0.00 21 -0.31 0.75 0.00 58 -0.32 0.72 0.00 28 0.77 
p-value 0.10    0.003    0.03     
Plasma FA Baseline 3.52 10.88 0.00 23 11.54 36.62 0.00 59 2.66 5.42 0.00 30 0.26 
(nmol/L) Follow up 30.10 60.25 3.80 23 40.06 73.03 10.70 59 33.29 46.15 15.10 30 0.79 
Difference 26.59 52.75 2.80 23 28.52 57.26 6.00 59 30.63 43.97 10.90 30 0.96 
p-value 0.02    0.003     0.007     
IL-8 Baseline 10.48 6.13 9.82 24 10.19 7.45 7.50 62 12.69 21.75 8.59 32 0.66 
(pg/mL) Follow up 11.85 11.51 8.38 24 9.75 7.06 7.55 62 10.32 11.22 7.46 32 0.65 
Difference 1.37 11.56 -1.06 24 -0.44 6.82 -0.11 62 -2.37 22.69 -0.56 32 0.60 
p-value 0.57    0.61    0.56     
B12 Baseline 510.57 207.73 521.00 21 559.51 257.31 532.00 55 569.14 288.16 477.00 29 0.70 
Follow up 555.90 245.83 580.00 21 580.84 261.72 615.00 55 584.24 268.88 599.00 29 0.92 
Difference 45.33 167.03 23.00 21 21.33 132.84 1.00 55 15.10 125.43 4.00 29 0.73 
p-value 0.23    0.24    0.52     
BMI Baseline 32.96 9.52 30.50 22 30.46 6.46 28.90 57 29.30 6.08 27.90 30 0.18 
Follow up 31.85 8.79 32.85 22 30.62 6.51 29.50 57 29.94 6.37 28.95 30 0.62 
Difference -1.12 4.51 0.00 22 0.16 1.11 0.00 57 0.64 1.79 0.50 30 0.03 
p-value 0.26    0.28    0.06     
 
 
 
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
CRP Baseline 1.31 1.39 0.80 22 1.42 2.08 0.70 57 1.37 3.18 0.70 29 0.98 
Follow up 0.75 0.40 0.65 22 1.30 2.65 0.50 57 1.01 1.07 0.50 29 0.54 
Difference -0.55 1.32 -0.10 22 -0.12 1.49 0.00 57 -0.36 3.08 -0.10 29 0.67 
p-value 0.06    0.55    0.53     
MCP-1 Baseline 425.57 325.89 328.00 23 361.11 187.48 320.00 63 369.44 176.48 348.00 32 0.47 
Follow up 492.30 366.70 446.00 23 410.76 191.59 401.00 63 400.78 196.70 359.50 32 0.30 
Difference 66.74 367.86 52.00 23 49.65 126.66 57.00 63 31.34 137.13 29.00 32 0.81 
p-value 0.39    0.003    0.21     
PGA Baseline 43.23 18.95 41.00 22 45.55 21.99 45.50 58 47.25 19.45 43.50 28 0.79 
Follow up 29.23 15.47 29.50 22 25.60 16.12 24.50 58 29.25 14.86 28.00 28 0.49 
Difference -14.00 25.15 -7.50 22 -19.95 22.98 -15.00 58 -18.00 28.61 -14.50 28 0.64 
p-value 0.02    <.0001    0.003     
Plasma  Baseline 61.52 36.09 50.50 23 52.88 31.45 46.10 59 52.90 26.22 46.40 30 0.50 
5-MTHF  Follow up 36.22 19.45 27.80 23 44.54 40.99 40.40 59 33.96 15.74 29.60 30 0.28 
(nmol/L) Difference -25.30 40.56 -17.40 23 -8.34 54.38 -10.80 59 -18.94 24.58 -14.55 30 0.27 
p-value 0.007    0.24    0.002     
Ratio  Baseline 40.51 20.26 40.73 22 45.44 22.07 44.24 57 32.94 21.63 38.96 29 0.04 
5-MTHF: Follow up 27.86 20.61 20.97 22 41.20 44.39 32.16 57 23.64 17.74 21.34 29 0.06 
THF Difference -12.65 19.12 -15.93 22 -4.24 46.02 -10.68 57 -9.30 14.76 -4.15 29 0.60 
p-value 0.005    0.49    0.002     
 
 
 
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
RBC  Baseline 25.98 41.01 13.02 22 19.70 27.28 11.28 57 38.43 68.34 12.57 29 0.19 
5,10-MTHF  Follow up 27.913 32.91 16.04 22 23.34 33.56 12.20 57 44.75 80.92 12.94 29 0.18 
(nmol/L) Difference 1.93 20.88 0.95 22 3.64 8.85 0.19 57 6.32 19.33 1.29 29 0.57 
p-value 0.67    0.003    0.09     
RBC  Baseline 1383.06 693.37 1257.85 22 1272.32 552.96 1147.20 57 1209.45 551.02 1149.60 29 0.57 
5-MTHF  Follow up 1027.01 348.45 1008.15 22 1158.23 568.02 1040.70 57 1096.84 577.71 1085.60 29 0.61 
(nmol/L) Difference -356.05 468.16 -189.15 22 -114.09 503.37 -220.10 57 -112.61 376.27 -121.20 29 0.10 
p-value 0.002    0.09    0.12     
RBC THF Baseline 78.15 134.04 30.50 22 62.05 108.77 27.30 57 145.68 286.17 39.00 29 0.12 
(nmol/L) Follow up 85.45 119.63 50.50 22 66.19 108.49 30.30 57 147.84 270.31 59.30 29 0.11 
Difference 7.30 45.16 4.35 22 4.14 42.84 3.10 57 2.17 103.32 9.50 29 0.96 
p-value 0.46    0.47    0.91     
tHcy Baseline 11.16 2.26 11.60 23 10.69 4.09 9.40 59 10.05 3.03 9.05 30 0.51 
Follow up 10.68 1.77 10.30 23 10.39 2.96 10.00 59 10.24 2.35 10.05 30 0.83 
Difference -0.48 1.75 -0.30 23 -0.30 3.48 -0.40 59 0.19 3.13 0.65 30 0.69 
p-value 0.20    0.51    0.74     
RBC Total  Baseline 1481.50 681.86 1400.90 22 1346.73 573.97 1246.00 57 1388.62 539.14 1295.90 29 0.66 
folate  Follow up 1137.74 373.75 1063.00 22 1241.92 604.30 1119.40 57 1284.31 538.82 1197.30 29 0.63 
(nmol/L) Difference -343.76 466.33 -229.60 22 -104.81 513.57 -204.80 57 -104.31 401.69 -84.10 29 0.12 
p-value 0.002    0.13    0.17     
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype 
 
 
 
Table 3 Effects of TYMS 5’ VNTR on variables at baseline, follow-up and difference 
 2R/2R 2R/3R 3R/4R 3R/3R  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean n Mean St Dev Median n p1 
ARA class Baseline 2.14 0.65 2.00 21 2.12 0.70 2.00 49 2.00 1 1.89 0.75 2.00 36 0.44 
Follow up 1.95 0.74 2.00 21 1.73 0.64 2.00 49 2.00 1 1.67 0.53 2.00 36 0.40 
Difference -0.19 0.75 0.00 21 -0.39 0.64 0.00 49 0.00 1 -0.22 0.76 0.00 36 0.60 
p2 0.25    <.0001      0.09     
Plasma FA Baseline 17.59 47.00 1.00 23 3.40 15.32 0.00 54 0.00 1 7.45 23.95 0.00 34 0.22 
(nmol/L) Follow up 62.05 105.69 30.80 23 26.21 40.68 4.55 54 0.00 1 35.66 54.34 15.60 34 0.14 
Difference 44.46 73.98 13.50 23 22.80 40.19 3.10 54 0.00 1 28.21 53.16 15.60 34 0.39 
p2 0.009    0.0001      0.004     
IL-8 Baseline 12.87 6.74 10.88 24 11.86 17.08 8.37 57 4.43 1 8.33 5.99 6.61 36 0.46 
(pg/mL) Follow up 11.98 8.65 8.86 24 10.85 11.21 7.12 57 4.86 1 8.56 5.54 7.10 36 0.46 
Difference -0.89 6.88 0.04 24 -1.01 18.59 -1.17 57 0.44 1 0.24 6.74 -0.32 36 0.98 
p2 0.53    0.68      0.84     
B12 Baseline 554.32 291.42 497.50 22 535.70 253.19 521.50 50 267.00 1 586.03 237.92 539.00 32 0.58 
Follow up 539.36 267.04 468.50 22 583.30 268.25 613.50 50 277.00 1 601.72 239.45 634.00 32 0.55 
Difference -14.95 127.70 -24.00 22 47.60 143.87 21.00 50 10.00 1 15.69 132.39 8.00 32 0.34 
p2 0.59    0.02      0.51     
BMI Baseline 28.10 5.23 28.00 22 31.76 7.86 29.50 51 26.60 1 30.74 6.85 30.90 35 0.22 
Follow up 28.55 5.42 27.50 22 31.59 7.63 30.00 51 27.60 1 30.78 6.73 31.30 35 0.37 
Difference 0.45 1.10 0.10 22 -0.17 3.06 0.10 51 1.00 1 0.04 1.94 -0.10 35 0.76 
p2 0.07    0.70      0.90     
 
 
 
 2R/2R 2R/3R 3R/4R 3R/3R  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean n Mean St Dev Median n p1 
CRP Baseline 1.68 2.76 0.60 19 1.33 2.58 0.70 52 0.80 1 1.32 1.59 0.75 36 0.94 
Follow up 1.91 4.25 0.70 19 0.75 0.61 0.50 52 0.30 1 1.23 1.41 0.60 36 0.18 
Difference 0.23 1.98 -0.10 19 -0.58 2.31 -0.10 52 -0.50 1 -0.09 1.46 -0.05 36 0.45 
p2 0.63    0.08      0.71     
MCP-1 Baseline 343.56 143.70 320.00 25 426.52 277.92 356.50 56 219.00 1 324.08 121.71 326.00 36 0.10 
Follow up 476.84 325.29 428.00 25 433.02 232.44 376.50 56 230.00 1 378.50 157.81 372.50 36 0.35 
Difference 133.28 247.37 83.00 25 6.50 218.30 18.50 56 11.00 1 54.42 75.78 48.00 36 0.06 
p2 0.01    0.82      0.0001     
PGA Baseline 48.14 23.27 43.00 21 42.66 19.96 39.50 50 76.00 1 47.11 19.70 45.00 36 0.30 
Follow up 28.48 16.73 25.00 21 26.22 15.47 27.00 50 28.00 1 28.06 15.79 27.50 36 0.93 
Difference -19.67 29.10 -12.00 21 -16.44 24.66 -13.50 50 -48.00 1 -19.06 22.81 -11.50 36 0.62 
p2 0.006    <.0001      <.0001     
Plasma  Baseline 63.49 26.93 61.60 23 48.82 31.00 41.95 54 20.20 1 58.97 32.57 54.60 34 0.13 
5-MTHF  Follow up 35.90 21.94 33.60 23 43.32 42.48 35.90 54 35.20 1 37.63 15.70 35.65 34 0.77 
(nmol/L) Difference -27.59 30.32 -24.90 23 -5.50 54.36 -9.40 54 15.00 1 -21.34 36.16 -16.05 34 0.16 
p2 0.0002    0.46      0.002     
Ratio  Baseline 41.54 27.35 36.39 21 37.86 21.31 39.23 52 30.44 1 46.03 19.38 46.82 34 0.39 
5-MTHF: Follow up 29.60 21.66 30.76 21 34.83 47.09 28.17 52 24.94 1 34.98 19.05 34.23 34 0.93 
THF Difference -11.94 23.69 -16.68 21 -3.04 47.21 -5.91 52 -5.50 1 -11.05 14.44 -13.22 34 0.69 
p2 0.03    0.64      <.0001     
 
 
 
 2R/2R 2R/3R 3R/4R 3R/3R  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean n Mean St Dev Median n p1 
RBC  Baseline 40.67 77.38 13.88 21 25.22 35.85 11.29 52 12.94 1 18.55 26.18 11.28 34 0.35 
5,10-MTHF  Follow up 50.17 93.37 15.50 21 27.29 35.89 12.37 52 11.58 1 22.29 28.50 12.40 34 0.23 
(nmol/L) Difference 9.50 18.79 0.19 21 2.08 17.18 0.49 52 -1.36 1 3.74 6.25 1.10 34 0.29 
p2 0.03    0.39      0.001     
RBC  Baseline 1352.14 730.40 1147.20 21 1186.71 578.82 1119.60 52 502.30 1 1394.63 451.66 1325.00 34 0.19 
5-MTHF  Follow up 1108.22 615.16 1022.30 21 1112.23 582.11 1002.10 52 616.10 1 1138.14 394.31 1129.40 34 0.82 
(nmol/L) Difference -243.92 474.04 -212.80 21 -74.48 506.86 -111.90 52 113.80 1 -256.49 399.63 -301.20 34 0.25 
p2 0.03    0.29      0.0007     
RBC THF Baseline 162.74 334.63 33.70 21 79.86 122.47 29.55 52 16.50 1 55.70 95.96 29.60 34 0.17 
(nmol/L) Follow up 156.75 313.92 54.10 21 89.91 124.92 37.80 52 24.70 1 57.30 84.25 33.85 34 0.21 
Difference -5.99 122.17 5.10 21 10.05 35.28 4.80 52 8.20 1 1.60 48.80 3.85 34 0.80 
p2 0.82    0.05      0.85     
tHcy Baseline 10.62 2.31 10.80 23 10.75 4.07 9.55 54 7.40 1 10.49 3.30 9.65 34 0.81 
Follow up 10.26 2.36 9.50 23 10.11 2.47 10.25 54 9.80 1 10.99 2.89 10.35 34 0.46 
Difference -0.37 2.09 -0.30 23 -0.64 3.49 -0.65 54 2.40 1 0.51 2.94 0.90 34 0.31 
p2 0.41    0.19      0.32     
RBC total  Baseline 1550.22 673.05 1399.50 21 1285.71 590.79 1167.30 52 518.80 1 1461.64 484.41 1351.10 34 0.11 
folate  Follow up 1310.83 575.31 1119.40 21 1225.04 602.56 1071.45 52 640.80 1 1211.58 432.05 1188.15 34 0.65 
(nmol/L) Difference -239.39 484.52 -204.80 21 -60.67 511.78 -85.45  122.00 1 -250.05 419.51 -295.80 34 0.23 
p2 0.03    0.40      0.001     
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype 
 
 
Table 4 Effects of TYMS 1494del6 on variables at baseline, follow-up and difference  
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
ARA class First 2.21 0.80 2.00 14 2.02 0.75 2.00 42 2.02 0.65 2.00 51 0.64 
Last 1.71 0.47 2.00 14 1.74 0.73 2.00 42 1.78 0.58 2.00 51 0.91 
Difference -0.50 0.85 0.00 14 -0.29 0.67 0.00 42 -0.24 0.68 0.00 51 0.46 
p2 0.05    0.008    0.02     
Plasma  First 3.99 12.13 0.00 15 6.49 25.19 0.00 43 9.31 31.96 0.00 54 0.77 
FA  Last 25.38 26.88 20.40 15 27.13 42.31 5.30 43 46.43 82.04 14.20 54 0.26 
(nmol/L) Difference 21.39 23.21 20.40 15 20.64 47.26 3.00 43 37.12 61.26 9.50 54 0.26 
p2 0.003    0.007    <.0001     
IL-8 First 7.92 6.97 6.21 15 13.36 18.85 8.82 47 9.68 5.29 8.00 56 0.22 
(pg/mL) Last 13.64 16.24 6.68 15 10.10 8.93 7.53 47 9.63 6.75 7.81 56 0.33 
Difference 5.72 16.30 0.37 15 -3.26 18.41 -1.17 47 -0.05 5.72 -0.46 56 0.08 
p2 0.20    0.23    0.95     
B12 First 498.60 246.53 465.00 15 588.47 262.69 565.00 38 541.52 254.68 494.50 52 0.47 
Last 555.40 253.65 599.00 15 588.34 262.23 622.00 38 574.52 261.46 527.50 52 0.91 
Difference 56.80 126.94 4.00 15 -0.13 165.77 0.00 38 33.00 115.36 21.00 52 0.33 
p2 0.11    0.99    0.04     
BMI First 29.38 4.47 30.00 13 30.20 6.69 28.50 43 31.31 7.98 29.20 53 0.60 
Last 29.68 4.81 30.00 13 30.18 7.14 29.40 43 31.32 7.27 29.50 53 0.63 
Difference 0.31 1.24 0.10 13 -0.02 3.06 0.10 43 0.01 2.04 0.00 53 0.91 
p2 0.39    0.96    0.97     
 
 
 
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
CRP First 1.53 2.43 0.60 15 1.84 3.20 0.90 42 0.97 0.96 0.60 51 0.19 
Last 1.99 1.85 1.40 15 1.28 2.91 0.60 42 0.72 0.60 0.50 51 0.08 
Difference 0.46 1.91 0.00 15 -0.56 2.84 -0.10 42 -0.25 0.85 -0.10 51 0.24 
p2 0.37    0.21    0.04     
MCP-1 First 301.93 130.70 296.00 15 410.91 266.57 346.00 47 366.39 185.88 319.50 56 0.22 
Last 357.40 179.68 329.00 15 435.38 220.03 434.00 47 432.18 263.32 386.50 56 0.51 
Difference 55.47 73.88 53.00 15 24.47 219.97 38.00 47 65.79 201.13 45.00 56 0.57 
p2 0.01    0.45    0.02     
PGA First 45.71 19.74 41.50 14 47.60 21.74 42.00 43 43.71 20.13 43.00 51 0.66 
Last 32.36 19.75 29.50 14 26.07 14.41 27.00 43 26.92 15.45 26.00 51 0.42 
Difference -13.36 26.79 -12.00 14 -21.53 22.74 -16.00 43 -16.78 26.11 -12.00 51 0.48 
p2 0.08    <.0001    <.0001     
Plasma  First 53.31 35.68 43.30 15 48.29 27.76 42.50 43 60.11 31.85 55.90 54 0.18 
5-MTHF  Last 44.77 22.26 43.10 15 41.62 46.81 33.20 43 37.38 17.26 38.75 54 0.68 
(nmol/L) Difference -8.55 37.78 -12.90 15 -6.67 56.32 -9.50 43 -22.73 36.52 -19.25 54 0.19 
p2 0.40    0.44    <.0001     
Ratio  First 46.58 23.27 54.00 15 42.56 22.52 39.28 42 38.25 21.30 40.77 51 0.38 
5-MTHF: Last 31.55 19.88 30.01 15 40.09 50.69 30.79 42 29.22 20.64 27.62 51 0.33 
THF Difference -15.03 13.09 -16.39 15 -2.48 53.06 -5.77 42 -9.03 16.61 -11.25 51 0.45 
p2 0.0006    0.76    0.0003     
 
 
 del/del ins/del ins/ins  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
RBC  First 23.05 30.81 11.51 15 19.14 23.22 11.83 42 32.54 59.13 11.30 51 0.35 
5,10-MTHF  Last 29.64 35.94 12.94 15 20.09 22.25 12.38 42 38.31 68.13 14.96 51 0.23 
(nmol/L) Difference 6.59 11.51 1.85 15 0.95 10.05 0.52 42 5.77 18.77 0.81 51 0.24 
p2 0.04    0.54    0.03     
RBC  First 1344.03 548.69 1271.40 15 1290.36 618.28 1132.45 42 1248.39 567.39 1123.90 51 0.84 
5-MTHF  Last 1232.42 513.24 1168.60 15 1173.27 643.66 1038.85 42 1032.51 421.39 1018.20 51 0.29 
(nmol/L) Difference -111.61 312.31 -125.80 15 -117.10 510.67 -105.70 42 -215.88 478.69 -212.80 51 0.55 
p2 0.19    0.14    0.002     
RBC THF First 84.80 148.31 28.50 15 54.12 79.91 29.95 42 116.38 237.09 31.50 51 0.25 
(nmol/L) Last 89.43 128.10 36.50 15 65.21 101.13 36.35 42 114.90 220.40 38.90 51 0.38 
Difference 4.63 72.51 3.90 15 11.09 30.21 5.85 42 -1.49 81.26 3.50 51 0.65 
p2 0.81    0.02    0.90     
tHcy First 11.91 5.78 11.00 15 10.83 3.14 10.30 43 10.09 2.88 9.25 54 0.18 
Last 11.43 3.20 11.20 15 10.32 2.63 10.30 43 10.19 2.34 9.85 54 0.25 
Difference -0.48 4.79 0.10 15 -0.51 3.14 -0.60 43 0.11 2.43 -0.05 54 0.58 
p2 0.70    0.29    0.74     
RBC First 1446.64 577.62 1314.30 15 1355.84 627.35 1247.95 42 1391.79 561.03 1397.70 51 0.87 
Total Last 1345.23 517.36 1205.30 15 1253.26 664.00 1085.00 42 1181.35 438.79 1081.00 51 0.57 
folate Difference -101.41 361.58 -117.00 15 -102.58 515.10 -80.25 42 -210.44 486.48 -222.40 51 0.51 
(nmol/L) p2 0.30    0.20    0.003     
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype  
 
 
Table 5  Effects of CCL2 (-2518)A>G on variables at baseline, follow-up and difference 
  AA AG GG  
Variable Visit Mean St Dev Median n Mean St Dev Median n Mean St Dev Median n p1 
MCP-1 Baseline 410.34 245.33 358.00 59 358.04 194.88 326.00 47 276.83 101.13 276.00 12 0.12 
Follow up 445.51 188.41 450.00 59 429.49 299.49 359.00 47 296.25 120.45 283.50 12 0.14 
Difference 35.17 202.09 53.00 59 71.45 213.32 43.00 47 19.42 76.41 16.00 12 0.56 
p2 0.19    0.03    0.40     
1p value by GLM for difference among genotypes for a given variable 
2p value by t test for difference from baseline to follow-up for an individual genotype
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         Table 6 Relationship between MTHFR C677T  
and toxicities 
 
Any  
Toxicity 
Attributable 
Toxicity 
MTHFR 
C677T No Yes No Yes 
CC 38 
40.672 
31.93 
69.09 
43.18 
17 
14.328 
14.29 
30.91 
54.84 
51 
52.227 
42.86 
92.73 
45.13 
4 
2.7731 
3.36 
7.27 
66.67 
CT 42 
39.193 
35.29 
79.25 
47.73 
11 
13.807 
9.24 
20.75 
35.48 
52 
50.328 
43.70 
98.11 
46.02 
1 
2.6723 
0.84 
1.89 
16.67 
TT 8 
8.1345 
6.72 
72.73 
9.09 
3 
2.8655 
2.52 
27.27 
9.68 
10 
10.445 
8.40 
90.91 
8.85 
1 
0.5546 
0.84 
9.09 
16.67 
p* 0.50 0.34 
          *p value by Fisher’s Exact test 
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       Table 7 Relationship between MTHFR A1298C  
and toxicities 
 
Any  
Toxicity 
Attributable 
Toxicity 
MTHFR 
A1298C No Yes No Yes 
AA 40 
36.975 
33.61 
80.00 
45.45 
10 
13.025 
8.40 
20.00 
32.26 
48 
47.479 
40.34 
96.00 
42.48 
2 
2.521 
1.68 
4.00 
33.33 
AC 43 
45.849 
36.13 
69.35 
48.86 
19 
16.151 
15.97 
30.65 
61.29 
59 
58.874 
49.58 
95.16 
52.21 
3 
3.1261 
2.52 
4.84 
50.00 
CC 5 
5.1765 
4.20 
71.43 
5.68 
2 
1.8235 
1.68 
28.57 
6.45 
6 
6.6471 
5.04 
85.71 
5.31 
1 
0.3529 
0.84 
14.29 
16.67 
p* 0.41 0.46 
         *p value by Fisher’s Exact test 
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            Table 8 Relationship between DHFR c.86+60_78  
and toxicities 
 
Any  
Toxicity 
Attributable 
Toxicity 
DHFR 
c.86+60_78 No Yes No Yes 
del/del 19 
17.748 
15.97 
79.17 
21.59 
5 
6.2521 
4.20 
20.83 
16.13 
24 
22.79 
20.17 
100.00 
21.24 
0 
1.2101 
0.00 
0.00 
0.00 
ins/del 47 
46.588 
39.50 
74.60 
53.41 
16 
16.412 
13.45 
25.40 
51.61 
60 
59.824 
50.42 
95.24 
53.10 
3 
3.1765 
2.52 
4.76 
50.00 
ins/ins 22 
23.664 
18.49 
68.75 
25.00 
10 
8.3361 
8.40 
31.25 
32.26 
29 
30.387 
24.37 
90.63 
25.66 
3 
1.6134 
2.52 
9.38 
50.00 
p* 0.70 0.34 
         *p value by Fisher’s Exact test 
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     Table 9 Relationship between TYMS  5’ VNTR  
and toxicities 
 
Any  
Toxicity 
Attributable 
Toxicity 
TYMS  5’ 
VNTR No Yes No Yes 
2R/2R 19 
18.487 
15.97 
76.00 
21.59 
6 
6.5126 
5.04 
24.00 
19.35 
25 
23.739 
21.01 
100.00 
22.12 
0 
1.2605 
0.00 
0.00 
0.00 
2R/3R 42 
42.151 
35.29 
73.68 
47.73 
15 
14.849 
12.61 
26.32 
48.39 
53 
54.126 
44.54 
92.98 
46.90 
4 
2.8739 
3.36 
7.02 
66.67 
2R/4R 0 
0.7395 
0.00 
0.00 
0.00 
1 
0.2605 
0.84 
100.00 
3.23 
1 
0.9496 
0.84 
100.00 
0.88 
0 
0.0504 
0.00 
0.00 
0.00 
3R/3R 27 
26.622 
22.69 
75.00 
30.68 
9 
9.3782 
7.56 
25.00 
29.03 
34 
34.185 
28.57 
94.44 
30.09 
2 
1.8151 
1.68 
5.56 
33.33 
p* 0.51 0.50 
         *p value by Fisher’s Exact test 
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     Table 10 Relationship between TYMS 1494del6  
and toxicities 
 
Any  
Toxicity 
Attributable 
Toxicity 
TYMS 
1494del6 No Yes No Yes 
del/del 11 
11.092 
9.24 
73.33 
12.50 
4 
3.9076 
3.36 
26.67 
12.90 
13 
14.244 
10.92 
86.67 
11.50 
2 
0.7563 
1.68 
13.33 
33.33 
ins/del 33 
35.496 
27.73 
68.75 
37.50 
15 
12.504 
12.61 
31.25 
48.39 
44 
45.58 
36.97 
91.67 
38.94 
4 
2.4202 
3.36 
8.33 
66.67 
ins/ins 44 
41.412 
36.97 
78.57 
50.00 
12 
14.588 
10.08 
21.43 
38.71 
56 
53.176 
47.06 
100.00 
49.56 
0 
2.8235 
0.00 
0.00 
0.00 
p* 0.54 0.02 
         *p value by Fisher’s Exact test 
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Table 11 Genes Up Regulated by PMX in Lo Cells. 
Transcript 
ID 
Gene Name Gene Symbol RefSeq p-value Corrected 
p-value 
Fold-
Change 
8147145 ATPase, H+ transporting, 
lysosomal 38kDa, V0 subunit 
d2 
ATP6V0D2 NM_152565 0.016141 0.129483 6.38 
8095744 amphiregulin AREG NM_001657 0.000961 0.022777 5.59 
7904431 similar to hydroxy-delta-5-
steroid dehydrogenase, 3 beta- 
and steroid delta-isomerase 1 
LOC391081 XR_019377 0.018020 0.138931 5.23 
8122265 tumor necrosis factor, 
alpha-induced protein 3 
TNFAIP3 NM_006290 0.005367 0.065315 4.81 
8112198 actin, beta-like 2 ACTBL2 NM_001017992 0.001452 0.029050 4.27 
8058708 ATP-binding cassette, sub-
family A (ABC1), member 12 
ABCA12 NM_173076 0.014202 0.120530 4.27 
8054722 interleukin 1, beta IL1B NM_000576 0.028791 0.183832 4.22 
7964460 DNA-damage-inducible 
transcript 3 
DDIT3 NM_004083 6.96E-06 0.001195 4.16 
8044021 interleukin 1 receptor-like 1 IL1RL1 NM_016232 0.004585 0.059709 4.15 
8108370 early growth response 1 EGR1 NM_001964 0.002955 0.045272 4.12 
7938746 MAS-related GPR, member X4 MRGPRX4 NM_054032 0.001222 0.026274 4.09 
8104901 interleukin 7 receptor IL7R NM_002185 0.017785 0.137758 4.09 
8166469 spermidine/spermine N1-
acetyltransferase 1 
SAT1 NR_027783 0.000161 0.007422 3.86 
8033257 complement component 3 C3 NM_000064 0.000819 0.020516 3.62 
8031570 ret finger protein-like 4A RFPL4A NM_001145014 0.018299 0.140046 3.61 
8019570 keratin associated protein 4-11 KRTAP4-11 NM_033059 0.036823 0.212270 3.55 
8015218 keratin associated protein 4-8 KRTAP4-8 NM_031960 0.028429 0.182364 3.48 
8007115 keratin associated protein 4-9 KRTAP4-9 NM_001146041 0.026097 0.173051 3.44 
8085393 transmembrane protein 40 TMEM40 NM_018306 0.002458 0.040423 3.40 
8136336 aldo-keto reductase family 1, 
member B10 (aldose reductase) 
AKR1B10 NM_020299 0.047876 0.247352 3.34 
7921144 SH2 domain protein 2A SH2D2A NM_001161441 0.001398 0.028354 3.29 
8163825 TNF receptor-associated 
factor 1 
TRAF1 NM_005658 7.63E-06 0.001224 3.29 
7943413 baculoviral IAP repeat-
containing 3 
BIRC3 NM_001165 0.000059 0.004088 3.17 
8112596 ankyrin repeat, family A 
(RFXANK-like), 2 
ANKRA2 NM_023039 0.000039 0.003094 3.13 
7904429 hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and 
steroid delta-isomerase 1  
HSD3B1 ENST00000235547 0.033320 0.200497 3.10 
8054712 interleukin 1, alpha IL1A NM_000575 0.001061 0.024184 3.05 
7962884 Rho family GTPase 1 RND1 NM_014470 0.001782 0.032775 2.94 
7918657 protein tyrosine phosphatase, 
non-receptor type 22 
(lymphoid) 
PTPN22 NM_015967 0.047767 0.247028 2.90 
8134564 myosin, heavy chain 16 
pseudogene 
MYH16 NR_002147 0.000284 0.010600 2.79 
8059376 serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 2 
SERPINE2 NM_001136529 0.010201 0.098064 2.79 
8012326 arachidonate lipoxygenase 3 ALOXE3 NM_021628 0.012244 0.110374 2.78 
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8092726 claudin 1 CLDN1 NM_021101 0.008294 0.086481 2.77 
8037205 carcinoembryonic antigen-
related cell adhesion molecule 
1 (biliary glycoprotein) 
CEACAM1 NM_001712 0.000978 0.023101 2.77 
7914202 small nucleolar RNA host gene 
12 (non-protein coding) 
SNHG12 AY277594 0.000630 0.017502 2.72 
8169263 V-set and immunoglobulin 
domain containing 1  
VSIG1 NM_182607 0.010864 0.102253 2.71 
7959102  heat shock 22kDa protein 8 HSPB8 NM_014365 0.004435 0.058514 2.68 
8023688 serpin peptidase inhibitor, 
clade B (ovalbumin), member 4 
SERPINB4 NM_002974 0.001367 0.028035 2.68 
7974870 small nuclear RNA activating 
complex, polypeptide 1, 43kDa 
SNAPC1 NM_003082 0.012056 0.109176 2.67 
7902660 WD repeat domain 63 WDR63 NM_145172 0.001671 0.031458 2.62 
7961187 killer cell lectin-like receptor 
subfamily C, member 1 
KLRC1 NM_002259 0.011652 0.106506 2.62 
8075310 leukemia inhibitory factor 
(cholinergic differentiation 
factor) 
LIF NM_002309 0.000625 0.017467 2.56 
8139207 inhibin, beta A INHBA NM_002192 0.031261 0.193165 2.54 
7975268 arginase, type II ARG2 NM_001172 3.68E-07 0.000254 2.52 
8083743 ADP-ribosylation factor-like 
14 
ARL14 NM_025047 0.034753 0.205753 2.51 
7939314 ets homologous factor EHF NM_012153 0.011295 0.104278 2.51 
7905515 keratinocyte proline-rich 
protein 
KPRP NM_001025231 0.016740 0.132396 2.49 
8154233 CD274 molecule CD274 NM_014143 0.000847 0.020858 2.48 
8040103 inhibitor of DNA binding 2, 
dominant negative helix-loop-
helix protein 
ID2 NM_002166 0.024423 0.166544 2.48 
7912145 tumor necrosis factor 
receptor superfamily, 
member 9 
TNFRSF9 NM_001561 1.94E-06 0.000622 2.46 
8094938 NIPA-like domain containing 1 NIPAL1 NM_207330 0.001806 0.033074 2.44 
8092741 urotensin 2 domain containing UTS2D NM_198152 0.042195 0.230483 2.42 
7905517 late cornified envelope 1F LCE1F NM_178354 0.036618 0.211893 2.41 
8169378 retrotransposon gag domain 
containing 1 
RGAG1 NM_020769 0.004519 0.059046 2.40 
8123893 male germ cell-associated 
kinase 
MAK NM_005906 0.000254 0.009958 2.39 
7979269 GTP cyclohydrolase 1 GCH1 NM_000161 0.000091 0.005317 2.39 
8026971 interferon, gamma-inducible 
protein 30 
IFI30 NM_006332 0.014586 0.122532 2.36 
7902227 growth arrest and DNA-
damage-inducible, alpha 
GADD45A NM_001924 3.23E-07 0.000251 2.35 
8029693 FBJ murine osteosarcoma viral 
oncogene homolog B 
FOSB NM_006732 0.000293 0.010751 2.34 
7932598 enkurin, TRPC channel 
interacting protein 
ENKUR NM_145010 0.003085 0.046686 2.34 
8080911 kelch repeat and BTB (POZ) 
domain containing 8 
KBTBD8 NM_032505 0.001256 0.026723 2.34 
8037079 ATPase, Na+/K+ transporting, 
alpha 3 polypeptide 
ATP1A3 NM_152296 0.002554 0.041389 2.33 
7920193 late cornified envelope 1C LCE1C NM_178351 0.001911 0.034425 2.33 
7934936 solute carrier family 16, 
member 12 (monocarboxylic 
acid transporter 12) 
SLC16A12 NM_213606 0.017297 0.135287 2.31 
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8039484 interleukin 11 IL11 NM_000641 0.000158 0.007336 2.31 
8174598 interleukin 13 receptor, alpha 
2 
IL13RA2 NM_000640 2.22E-07 0.000212 2.31 
8147661 sperm associated antigen 1 SPAG1 NM_003114 0.007123 0.078105 2.29 
8144874 nervous system abundant 
protein 11 
NSAP11 AY176665 0.029640 0.187020 2.29 
8160531 chromosome 9 open reading 
frame 72 
C9orf72 NM_018325 2.04E-07 0.000203 2.27 
7930074 nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2 (p49/p100) 
NFKB2 NM_002502 0.000011 0.001485 2.27 
7992828 interleukin 32 IL32 NM_001012631 1.84E-06 0.000606 2.25 
7900365 major facilitator superfamily 
domain containing 2 
MFSD2 NM_001136493 0.000624 0.017467 2.25 
8090180 mucin 13, cell surface 
associated 
MUC13 NM_033049 0.023396 0.162486 2.25 
8109563 NIPA-like domain containing 4 NIPAL4 NM_001099287 0.000272 0.010276 2.24 
8156770 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
12 (GalNAc-T12) 
GALNT12 NM_024642 0.023475 0.162803 2.22 
7920165 filaggrin FLG NM_002016 0.024245 0.165863 2.22 
8150698 snail homolog 2 (Drosophila) SNAI2 NM_003068 0.005022 0.062573 2.22 
8050702 tumor protein p53 inducible 
protein 3 
TP53I3 NM_004881 0.001233 0.026453 2.22 
7905428 tuftelin 1 TUFT1 NM_020127 0.013496 0.116908 2.21 
8042503 MAX dimerization protein 1 MXD1 NM_002357 0.000575 0.016435 2.20 
8154295 interleukin 33 IL33 NM_033439 2.02E-06 0.000633 2.20 
8095680 interleukin 8 IL8 NM_000584 0.041392 0.227552 2.19 
8146921 retinol dehydrogenase 10 (all-
trans) 
RDH10 NM_172037 0.006286 0.072256 2.19 
7929750 ectonucleoside triphosphate 
diphosphohydrolase 7 
ENTPD7 NM_020354 0.000082 0.004994 2.18 
7921773 poliovirus receptor-related 4 PVRL4 NM_030916 0.000020 0.002047 2.17 
7971461 lymphocyte cytosolic protein 1 
(L-plastin) 
LCP1 NM_002298 0.028579 0.183082 2.16 
8151816 GTP binding protein 
overexpressed in skeletal 
muscle 
GEM NM_005261 0.000049 0.003586 2.16 
8089785 popeye domain containing 2 POPDC2 NM_022135 5.22E-06 0.001017 2.16 
7927732 AT rich interactive domain 5B 
(MRF1-like) 
ARID5B NM_032199 0.008971 0.090880 2.16 
7968883 chromosome 13 open reading 
frame 31 
C13orf31 NM_153218 0.001025 0.023762 2.15 
7997642 cysteine-rich secretory protein 
LCCL domain containing 2 
CRISPLD2 NM_031476 0.046441 0.243340 2.15 
7909610 activating transcription factor 3 ATF3 NM_001040619 0.000017 0.001902 2.14 
8153322 activity-regulated cytoskeleton-
associated protein 
ARC NM_015193 0.000122 0.006227 2.14 
8158022 zinc finger protein 79 ZNF79 NM_007135 0.000025 0.002362 2.13 
7909225 dual-specificity tyrosine-(Y)-
phosphorylation regulated 
kinase 3 
DYRK3 NM_001004023 5.05E-06 0.001003 2.13 
7899192 ribosomal protein S6 kinase, 
90kDa, polypeptide 1 
RPS6KA1 NM_002953 0.000243 0.009602 2.13 
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7975779 FBJ murine osteosarcoma viral 
oncogene homolog 
FOS NM_005252 0.000773 0.019763 2.13 
7962689 vitamin D (1,25- 
dihydroxyvitamin D3) receptor 
VDR NM_001017535 0.005121 0.063416 2.12 
8030128 protein phosphatase 1, 
regulatory (inhibitor) subunit 
15A 
PPP1R15A NM_014330 2.39E-08 0.000084 2.12 
8014956 nuclear receptor subfamily 1, 
group D, member 1 
NR1D1 NM_021724 2.80E-07 0.000241 2.10 
8063386 CCAAT/enhancer binding 
protein (C/EBP), beta 
CEBPB NM_005194 0.000351 0.012045 2.10 
8077441 basic helix-loop-helix family, 
member e40 
BHLHE40 NM_003670 0.003429 0.049803 2.10 
7927082 hydroxysteroid (17-beta) 
dehydrogenase 7 pseudogene 2 
HSD17B7P2 NR_003086 0.000925 0.022211 2.10 
7951662 crystallin, alpha B CRYAB NM_001885 0.024667 0.167244 2.09 
8114572 heparin-binding EGF-like 
growth factor 
HBEGF NM_001945 0.003478 0.050204 2.09 
7935521 arginine vasopressin-induced 1 AVPI1 NM_021732 0.012569 0.112153 2.08 
8162940 ATP-binding cassette, sub-
family A (ABC1), member 1 
ABCA1 NM_005502 0.000058 0.004042 2.07 
8023043 proline-serine-threonine 
phosphatase interacting protein 
2 
PSTPIP2 NM_024430 0.024815 0.167890 2.06 
7995292 solute carrier family 6 
(neurotransmitter transporter, 
creatine), member 8  
SLC6A8 NM_005629 0.000290 0.010681 2.06 
7963774 zinc finger protein 385A ZNF385A NM_015481 0.002497 0.040842 2.04 
8135576 testis derived transcript (3 LIM 
domains) 
TES NM_015641 3.06E-06 0.000779 2.04 
8055688 Rho family GTPase 3 RND3 NM_005168 0.005357 0.065247 2.03 
7922976 prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
PTGS2 NM_000963 0.021185 0.153096 2.03 
8063369 ring finger protein 114 RNF114 NM_018683 2.51E-06 0.000688 2.03 
8023995 follistatin-like 3 (secreted 
glycoprotein) 
FSTL3 NM_005860 0.028031 0.180986 2.03 
8020702 TAF4b RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
105kDa 
TAF4B NM_005640 0.000109 0.005883 2.02 
7935425 ribosomal RNA processing 12 
homolog (S. cerevisiae) 
RRP12 NM_015179 0.000148 0.006983 2.01 
8105302 follistatin FST NM_006350 0.048702 0.249962 2.01 
7902290 cystathionase (cystathionine 
gamma-lyase) 
CTH NM_001902 0.006032 0.070752 2.01 
8002660 thioredoxin-like 4B TXNL4B NM_017853 7.40E-08 0.000126 2.00 
8097461 CCR4 carbon catabolite 
repression 4-like (S. cerevisiae)  
CCRN4L NM_012118 0.021407 0.153680 2.00 
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Table 12 Genes Down Regulated by PMX in Lo Cells 
Transcript 
ID 
Gene Name Gene Symbol RefSeq p-value Corrected  
p-value 
Fold-
Change 
8117594 histone cluster 1, H2bm HIST1H2BM NM_003521 7.30E-08 0.000126 -7.45 
7994109 polo-like kinase 1 
(Drosophila) 
PLK1 NM_005030 1.08E-09 0.000016 -5.42 
8079237 kinesin family member 15 KIF15 NM_020242 3.91E-07 0.000254 -4.76 
8008784 proline rich 11 PRR11 NM_018304 3.71E-08 0.000097 -4.47 
7991406 protein regulator of 
cytokinesis 1 
PRC1 NM_003981 3.33E-09 0.000032 -4.32 
8168794 centromere protein I CENPI NM_006733 2.91E-08 0.000084 -3.86 
8054580 budding uninhibited by 
benzimidazoles 1 homolog 
(yeast) 
BUB1 NM_004336 9.13E-08 0.000138 -3.77 
8047288 shugoshin-like 2 (S. pombe) SGOL2 NM_152524 3.68E-07 0.000254 -3.69 
7916898 DEP domain containing 1 DEPDC1 NM_001114120 0.000013 0.001615 -3.46 
7940147 family with sequence 
similarity 111, member B 
FAM111B NM_198947 1.04E-06 0.000429 -3.30 
8056572 SPC25, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
SPC25 NM_020675 3.72E-07 0.000254 -3.25 
8014974 topoisomerase (DNA) II alpha 
170kDa 
TOP2A NM_001067 3.54E-06 0.000851 -3.23 
8055426 minichromosome maintenance 
complex component 6 
MCM6 NM_005915 3.22E-07 0.000251 -3.20 
7983306 WD repeat domain 76 WDR76 NM_024908 4.57E-06 0.000965 -3.19 
8152976 transmembrane protein 71 TMEM71 NM_144649 0.000012 0.001551 -3.19 
7966878 citron (rho-interacting, 
serine/threonine kinase 21) 
CIT NM_007174 5.41E-06 0.001033 -3.13 
7906930 NUF2, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
NUF2 NM_145697 4.05E-07 0.000254 -3.12 
8124394 histone cluster 1, H2bb HIST1H2BB NM_021062 0.000017 0.001875 -3.03 
8108301 kinesin family member 20A KIF20A NM_005733 0.001327 0.027462 -2.99 
8102643 cyclin A2 CCNA2 NM_001237 8.56E-06 0.001265 -2.99 
8034122 SPC24, NDC80 kinetochore 
complex component, homolog 
(S. cerevisiae) 
SPC24 NM_182513 8.82E-07 0.000417 -2.98 
7955063 transmembrane protein 106C  TMEM106C NM_001143842 5.94E-06 0.001085 -2.95 
8043602 non-SMC condensin I 
complex, subunit H 
NCAPH NM_015341 2.78E-07 0.000241 -2.93 
8112376 centromere protein K CENPK NM_022145 0.000016 0.001813 -2.92 
8149955 PDZ binding kinase PBK NM_018492 1.09E-06 0.000435 -2.90 
8168146 kinesin family member 4A  KIF4A NM_012310 9.69E-07 0.000417 -2.89 
7909708 centromere protein F, 
350/400ka (mitosin) 
CENPF NM_016343 1.23E-07 0.000154 -2.87 
8077731 Fanconi anemia, 
complementation group D2 
FANCD2 NM_033084 1.67E-06 0.000578 -2.86 
7989647 KIAA0101 KIAA0101 NM_014736 1.03E-06 0.000429 -2.86 
8124527 histone cluster 1, H1b HIST1H1B NM_005322 0.000019 0.002026 -2.83 
7960340 forkhead box M1 FOXM1 NM_202002 1.79E-06 0.000606 -2.82 
7983969 cyclin B2 CCNB2 NM_004701 5.69E-06 0.001066 -2.80 
8003204 GINS complex subunit 2 (Psf2 GINS2 NM_016095 6.60E-07 0.000343 -2.80 
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homolog) 
8105828 cyclin B1 CCNB1 NM_031966 6.54E-06 0.001150 -2.77 
7903565 G-protein signaling modulator 
2 (AGS3-like, C. elegans) 
GPSM2 NM_013296 0.000384 0.012596 -2.77 
7989146 meiosis-specific nuclear 
structural 1 
MNS1 NM_018365 0.000019 0.002019 -2.76 
8117426 histone cluster 1, H2bh HIST1H2BH NM_003524 0.000011 0.001444 -2.76 
7982358 Rho GTPase activating protein 
11A 
ARHGAP11A NM_014783 2.24E-06 0.000658 -2.73 
7982663 budding uninhibited by 
benzimidazoles 1 homolog 
beta (yeast) 
BUB1B NM_001211 2.30E-06 0.000666 -2.63 
8179564 kinesin family member C1 KIFC1 NM_002263 9.22E-07 0.000417 -2.62 
8016139 kinesin family member 18B KIF18B NM_001080443 4.68E-06 0.000979 -2.60 
8063043 ubiquitin-conjugating enzyme 
E2C 
UBE2C NM_181802 4.73E-08 0.000097 -2.60 
7964271 primase, DNA, polypeptide 1 
(49kDa) 
PRIM1 NM_000946 4.05E-06 0.000899 -2.60 
7922219 selectin L SELL NM_000655 0.006407 0.073110 -2.56 
7979307 discs, large (Drosophila) 
homolog-associated protein 5 
DLGAP5 NM_014750 4.49E-06 0.000965 -2.55 
8137244 GTPase, IMAP family 
member 4 
GIMAP4 NM_018326 0.007764 0.082723 -2.55 
8173506 excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 6 
ERCC6L NM_017669 0.000019 0.002019 -2.55 
7974404 cyclin-dependent kinase 
inhibitor 3 
CDKN3 NM_005192 0.000517 0.015470 -2.54 
8117330 histone cluster 1, H3a  HIST1H3A NM_003529 0.000027 0.002445 -2.53 
8124524 histone cluster 1, H2ak HIST1H2AK NM_003510 0.000017 0.001875 -2.52 
7923086 asp (abnormal spindle) 
homolog, microcephaly 
associated (Drosophila) 
ASPM NM_018136 7.73E-07 0.000384 -2.51 
8056102 CD302 molecule CD302 NM_014880 0.034472 0.204608 -2.47 
8091715 latexin LXN NM_020169 0.010111 0.097485 -2.47 
7978846 polymerase (DNA directed), 
epsilon 2 (p59 subunit) 
POLE2 NM_002692 2.49E-06 0.000688 -2.46 
8107706 lamin B1 LMNB1 NM_005573 0.000011 0.001444 -2.45 
8124531 histone cluster 1, H3i HIST1H3I NM_003533 2.79E-06 0.000732 -2.44 
8132318 anillin, actin binding protein ANLN NM_018685 0.001586 0.030582 -2.42 
8001133 SHC SH2-domain binding 
protein 1 
SHCBP1 NM_024745 0.000186 0.008163 -2.42 
8144153 non-SMC condensin II 
complex, subunit G2 
NCAPG2 NM_017760 0.000069 0.004456 -2.41 
8091306 phospholipid scramblase 4 PLSCR4 NM_001128304 0.001593 0.030673 -2.40 
8092640 replication factor C (activator 
1) 4, 37kDa 
RFC4 NM_002916 1.55E-07 0.000171 -2.40 
7978712 C-type lectin domain family 
14, member A 
CLEC14A NM_175060 0.021066 0.152589 -2.39 
8071212 CDC45 cell division cycle 45-
like (S. cerevisiae) 
CDC45L NM_003504 0.000034 0.002819 -2.37 
8023575 collagen and calcium binding 
EGF domains 1 
CCBE1 NM_133459 0.000111 0.005913 -2.37 
8022612 zinc finger protein 521 ZNF521 NM_015461 0.035066 0.206522 -2.36 
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8124388 histone cluster 1, H3b HIST1H3B NM_003537 0.000186 0.008168 -2.36 
8019857 NDC80 homolog, kinetochore 
complex component (S. 
cerevisiae) 
NDC80 NM_006101 0.000013 0.001615 -2.35 
8043036 dihydrofolate reductase DHFR AK293146 0.000014 0.001696 -2.35 
7915612 patched homolog 2 
(Drosophila) 
PTCH2 ENST00000438067 0.010452 0.099871 -2.34 
7900699 cell division cycle 20 homolog 
(S. cerevisiae) 
CDC20 NM_001255 0.001607 0.030792 -2.34 
7916584 tumor-associated calcium 
signal transducer 2 
TACSTD2 NM_002353 0.010841 0.102100 -2.34 
8155214 maternal embryonic leucine 
zipper kinase 
MELK NM_014791 9.47E-07 0.000417 -2.32 
8117395 histone cluster 1, H2bf HIST1H2BF NM_003522 9.24E-06 0.001345 -2.31 
7982757 cancer susceptibility candidate 
5 
CASC5 NM_170589 3.73E-06 0.000876 -2.29 
8124391 histone cluster 1, H2ab HIST1H2AB NM_003513 2.65E-06 0.000713 -2.27 
7929258 kinesin family member 11 KIF11 NM_004523 6.67E-07 0.000343 -2.26 
8103728 high-mobility group box 2 HMGB2 NM_001130688 0.000026 0.002371 -2.26 
8176174 membrane protein, 
palmitoylated 1, 55kDa 
MPP1 NM_002436 0.002893 0.044729 -2.24 
8178399 nurim (nuclear envelope 
membrane protein) 
NRM NM_007243 0.000299 0.010886 -2.24 
8161755 aldehyde dehydrogenase 1 
family, member A1 
ALDH1A1 NM_000689 0.000010 0.001430 -2.24 
8098423 nei endonuclease VIII-like 3 
(E. coli) 
NEIL3 NM_018248 0.000046 0.003445 -2.23 
7900167 cell division cycle associated 
8 
CDCA8 NM_018101 2.24E-06 0.000658 -2.23 
7958031 chromosome 12 open reading 
frame 48 
C12orf48 AK302724 5.01E-06 0.001003 -2.22 
8097356 polo-like kinase 4 
(Drosophila) 
PLK4 NM_014264 0.000020 0.002047 -2.21 
8067167 aurora kinase A AURKA NM_198433 0.000010 0.001430 -2.21 
7999387 epithelial membrane protein 2 EMP2 NM_001424 0.001266 0.026804 -2.20 
7923189 kinesin family member 14 KIF14 NM_014875 0.000042 0.003262 -2.20 
7953914 C-type lectin domain family 
12, member B 
CLEC12B NM_205852 0.000104 0.005715 -2.19 
7934026 DNA replication helicase 2 
homolog (yeast) 
DNA2 NM_001080449 0.000381 0.012567 -2.19 
8005839 transmembrane protein 97 TMEM97 NM_014573 2.12E-06 0.000650 -2.16 
8015769 breast cancer 1, early onset BRCA1 NR_027676 0.000019 0.002019 -2.16 
8104912 S-phase kinase-associated 
protein 2 (p45) 
SKP2 NM_005983 1.64E-08 0.000084 -2.16 
8111234 cadherin 12, type 2 (N-
cadherin 2) 
CDH12 NM_004061 0.002944 0.045236 -2.15 
8093500 transforming, acidic coiled-
coil containing protein 3 
TACC3 NM_006342 5.49E-06 0.001034 -2.15 
7982889 nucleolar and spindle 
associated protein 1 
NUSAP1 NM_016359 0.000046 0.003460 -2.15 
8129458 Rho GTPase activating protein 
18 
ARHGAP18 NM_033515 0.001656 0.031325 -2.13 
8130739 ribosomal protein S6 kinase, 
90kDa, polypeptide 2 
RPS6KA2 NM_021135 0.026851 0.176170 -2.13 
8104234 thyroid hormone receptor 
interactor 13 
TRIP13 NM_004237 0.000058 0.004037 -2.13 
7933707 ZW10 interactor ZWINT NM_032997 5.07E-07 0.000304 -2.12 
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7971653 deleted in lymphocytic 
leukemia 2 (non-protein 
coding) 
DLEU2 NR_002612 0.000120 0.006152 -2.12 
7930380 adducin 3 (gamma) ADD3 NM_016824 0.006201 0.071825 -2.11 
8163807 PHD finger protein 19 PHF19 NM_015651 0.000093 0.005344 -2.11 
7974920 spectrin repeat containing, 
nuclear envelope 2 
SYNE2 NM_182914 0.028953 0.184093 -2.10 
8024900 ubiquitin-like with PHD and 
ring finger domains 1 
UHRF1 NM_001048201 0.000092 0.005344 -2.10 
8020495 Cdk5 and Abl enzyme 
substrate 1 
CABLES1 NM_138375 0.001644 0.031249 -2.10 
7953218 RAD51 associated protein 1 RAD51AP1 NM_001130862 7.17E-06 0.001224 -2.10 
7985829 Fanconi anemia, 
complementation group I 
FANCI NM_001113378 4.88E-06 0.000990 -2.10 
7915592 RNA, U5F small nuclear RNU5F M77840 0.001679 0.031506 -2.09 
7927710 cell division cycle 2, G1 to S 
and G2 to M 
CDC2 NM_001786 0.000318 0.011387 -2.09 
8040223 ribonucleotide reductase M2 RRM2 NM_001034 0.002209 0.037546 -2.08 
8109484 kinesin family member 4B KIF4B NM_001099293 7.86E-06 0.001232 -2.08 
8137250 GTPase, IMAP family 
member 2 
GIMAP2 NM_015660 0.001008 0.023540 -2.07 
8157534 centrosomal protein 110kDa CEP110 NM_007018 0.000463 0.014402 -2.07 
8054135 mannosyl (alpha-1,3-)-
glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, 
isozyme A 
MGAT4A NM_012214 0.000293 0.010751 -2.06 
8012403 aurora kinase B AURKB NM_004217 0.000021 0.002092 -2.06 
7958455 uracil-DNA glycosylase UNG NM_003362 3.25E-06 0.000795 -2.05 
7951535 KDEL (Lys-Asp-Glu-Leu) 
containing 2 
KDELC2 NM_153705 2.63E-08 0.000084 -2.05 
8072687 minichromosome maintenance 
complex component 5 
MCM5 NM_006739 0.000018 0.001912 -2.05 
7987636 Opa interacting protein 5 OIP5 NM_007280 0.000050 0.003598 -2.05 
8003503 Fanconi anemia, 
complementation group A 
FANCA NM_000135 3.22E-06 0.000793 -2.04 
8054479 mal, T-cell differentiation 
protein-like 
MALL NM_005434 0.017922 0.138444 -2.04 
8056323 fidgetin FIGN NM_018086 1.98E-06 0.000628 -2.03 
7970513 spindle and kinetochore 
associated complex subunit 3 
SKA3 NM_145061 0.001585 0.030582 -2.03 
8124510 histone cluster 1, H2bl HIST1H2BL NM_003519 0.000042 0.003233 -2.03 
8103466 follistatin-like 5 FSTL5 NM_020116 0.000043 0.003283 -2.02 
8128459 single-minded homolog 1 
(Drosophila) 
SIM1 NM_005068 0.000049 0.003586 -2.02 
7984540 kinesin family member 23 KIF23 NM_138555 8.32E-06 0.001244 -2.01 
8066136 retinoblastoma-like 1 (p107) RBL1 NM_002895 5.15E-06 0.001010 -2.01 
8102560 MAD2 mitotic arrest 
deficient-like 1 (yeast) 
MAD2L1 NM_002358 0.000477 0.014616 -2.01 
8108697 protocadherin beta 5 PCDHB5 NM_015669 0.023807 0.163920 -2.00 
8144036 X-ray repair complementing 
defective repair in Chinese 
hamter cells 2 
XRCC2 NM_005431 0.000046 0.003443 -2.00 
8137252 GTPase, IMAP family 
member 1 
GIMAP1 NM_130759 0.003755 0.052544 -2.00 
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